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1. Introduction 
The Human Immunodeficiency Virus-1 (HIV-1), the causative agent of the acquired 
immunodeficiency syndrome (AIDS), was described for the first time in 1983 [1, 2]. In the 
meantime, various classes of anti-retroviral drugs have been developed and combination 
therapy has improved the quality of life for millions of people affected. At the end of 2010 
more than 34 million people were living with HIV infection worldwide [3]. Despite the 
increased access to antiretroviral therapy, an extensive treatment gap persists between the 
low-/middle-income countries and well-developed ones. This resulted in 1.8 million HIV 
related deaths and 2.6 million newly infected persons in 2009 [3]. Even for those who have 
access to treatment, there is no cure, as current therapy regimens cannot eradicate the virus. 
Therefore, the control and ultimate eradication of this pathogen remains one of the most 
important challenges in today’s biomedical research. 
HIV belongs to the family of Retroviridae and the genus Lentivirus (lenti, Latin for “slow”), 
which is characterized by a long incubation period causing long-lasting illnesses [4]. An HIV 
particle has a spherical shape and a size of about 100 nm. It consists of an outer coat, called 
the viral envelope, and an inner capsid enclosing two copies of positive single stranded 
ribonucleic acid (RNA). The RNA genome is 9.5 kB large and is composed of nine genes 
encoding structural (Gag, Pol and Env), regulatory (Tat and Rev) and accessory (Nef, Vif, 
Vpr and Vpu) proteins [5]. HIV-1 mainly infects CD4+ cells such as CD4+ T cells, 
macrophages and dendritic cells (DCs). Infection is initiated by the binding of the viral 
envelope glycoprotein 120 (gp120) to the CD4 receptor of the host cell, resulting in a 
conformational change that allows gp120 to interact with one of the co-receptors, CCR5 or 
CXCR4.  
Binding of gp120 to the co-receptor induces further conformational changes that lead to the 
exposure of the fusion domain on glycoprotein 41 (gp41). Fusion of this domain with the 
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lipid cell membrane allows entry of the viral core into the host cell cytoplasm. This is 
followed by reverse transcription of the single-stranded RNA into double-stranded DNA, 
which becomes integrated into the host genome [6]. After DNA integration, HIV remains 
present as a latent DNA provirus which becomes active upon cell activation [7]. 
Transcription of the viral proteins eventually leads to the formation of mature and infectious 
virions [8]. 
HIV-1 can be transmitted “horizontally” through hetero- or homosexual contact or blood-
blood contact (e.g. blood transfusion or intravenous drug use) as well as “vertically” from 
mother-to-child [9]. The transmission of HIV strongly depends on the concentration of virus 
in the body fluids (genital secretions, plasma or breast milk), viral “fitness” properties and 
the host susceptibility at both the immunological and the cellular level [10].  
Clinically, an HIV-1 infection course can be divided in three stages: the primary or acute 
infection phase, the chronic phase (first asymptomatic and later non-AIDS defining 
symptoms) and the terminal AIDS defining illness. The first days after infection, the virus 
spreads from the portal of entry via regional lymph nodes throughout the body. It readily 
infects CD4+ T cells, producing new virions, which results in a high plasma viral load (VL). 
The virus finds its way to all lymphoid organs, but with a particularly massive viral 
production by the gastro-intestinal associated lymphoid tissue (GALT) is often observed. 
Remarkably, only a proportion of the newly infected patients experiences a clinical “acute 
phase syndrome”, characterized by mononucleosis- or flu-like symptoms, including fever, 
fatigue, sore throat, skin rash, enlarged lymph nodes, diarrhea, nausea and general malaise. 
In the first three to six weeks a rapid decline of CD4+ T cells is observed in the peripheral 
blood and even more pronounced in the GALT, which nonetheless remains an important 
HIV reservoir [11]. The appearance of HIV-1 specific cellular immune responses and the 
subsequent production of HIV-1 specific antibodies results in a sharp drop of viral load 
reaching a steady state viraemia, called the viral setpoint (usually within six months after 
infection). A dynamic equilibrium is then established between viral replication (fitness) and 
viral suppression by the immune system. Nevertheless, because of the limited regeneration 
capacity of the immune system (including thymic atrophy in adults) the number of CD4+ T 
cells will continue to gradually decrease during the chronic phase. This stage can last up to ten 
years and is characterized by lack of clinical symptoms of illness or relatively mild symptoms 
that often do not raise suspicion of HIV infection. Eventually the immune system becomes 
exhausted due to chronic immune activation and T-cell depletion as a result of direct 
cytopathic effects of infected cells, but even more by induction of apoptosis of uninfected 
bystander cell (CD4+ and CD8+ T cells) and degeneration of lymphoid organs. Opportunistic 
diseases, including serious infections or malignant tumors that are no longer controlled due to 
a loss of immune surveillance are the cause of AIDS-related deaths [10, 12, 13]. 
The majority (> 90 %) of infected individuals progresses to AIDS within about ten years after 
primary infection (normal progressors). Some individuals (around 5 %) remain 
asymptomatic for more than ten years with stable numbers of CD4+ T cells and low to 
intermediate viral loads (long term survivors and long term non progressors) [14]. Less than 
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1 % of infected individuals have viral  loads below 50 copies per ml for at least 1-2 years 
while untreated (elite controllers or HIV controllers) [15]. Some individuals remain 
uninfected, despite being highly exposed to HIV-1 (exposed seronegatives) [16]. 
The first effective antiretroviral drugs (all nucleoside analogues) became available at the end 
of the nineties. They were used in single and later in dual combinations, but could suppress 
the viral load (VL) only temporarily. This was due to the appearance of drug resistance [17]. 
Triple drug combinations called “highly active antiretroviral therapy” (HAART), are able to 
suppress VL in a more sustained way and hence can prevent the emergence of drug 
resistance. For a number of years viral suppression was only possible at the cost of a high 
medication burden and many side effects. During the last decade, however, HAART has 
become less complicated and better tolerated, which has converted HIV-1 infection into a 
chronic but treatable disease [18].  
It should be kept in mind, however, that HAART is not a treatment devoid of shortcomings. 
Firstly, a life-long commitment to the therapy remains mandatory to keep the virus under 
control and delay disease progression. Secondly, the treatment may cause toxic drug-related 
adverse effects such as cardiovascular complications [19], renal and hepatic diseases [20], 
lipodystrophy and diabetes mellitus, collectively called “metabolic syndrome” [21]. Thirdly, 
even though HAART restores the number of circulating CD4+ T cells to near normal levels, 
responses against HIV itself remain deficient [11, 22]. Finally, this costly treatment is not 
available for all infected persons, especially not in low- and middle-income countries in 
Africa, Asia and Latin America, where the numbers of patients are the highest and still 
increasing [3]. 
Therefore, there is a clear need for cheaper and more widely available therapies that can 
suppress and/or eliminate the viral reservoir even if the treatment is stopped or interrupted. 
Improving HIV-specific cell-mediated immunity by therapeutic vaccination is a generally 
accepted approach to tackle the problem.  
During the last decade immunotherapeutic vaccination strategies have been sought after to 
boost the immune system in order to control virus replication and to eliminate infected cells. 
These vaccines are largely based on ex vivo loading of dendritic cells with antigens and 
immune-stimulating molecules. This personalized process is time-consuming, labor 
intensive, and requires strict quality control. It should be stressed that high costs of the 
procedure together with the need to use sophisticated equipment, restrains its application in 
less developed countries.  
Recently, particulate antigen vehicles have been introduced in the field of vaccine design 
with the purpose to improve antigen delivery and to induce antigen specific immune 
responses. A variety of nano- and micro-carriers has been developed to deliver protein, 
peptides and/or nucleic acids to cells of the immune system. The intracellular fate of these 
particles depends on their physicochemical characteristics such as size, stability and charge. 
These in turn determine the efficiency with which the specific cargo is delivered to antigen-
presenting cells (APC) and the extent of antigen-specific immune responses induced. 
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2. HIV and the immune system 
2.1. Immune activation 
Chronic HIV-related immune activation is characterized by the inappropriate production of 
pro-inflammatory cytokines and overexpression of cellular activation and exhaustion 
markers. Most of these inflammatory responses induced by HIV are not directed toward 
HIV. They rather enhance susceptibility of target cells to HIV infection and enhance virus 
replication in already infected cells, which accelerates disease progression. This chronic, 
non-specific T cell activation leads to T cell exhaustion and apoptosis of CD4+ and CD8+ T 
cells [23]. Increased expressions of HLA-DR and CD38 molecules on CD8+ T cells correlate 
with a higher level of immune activation and constitute markers for bad prognosis, which 
are partly independent from actual CD4 T count and VL [24]. 
It remains unclear whether there is a single key mechanism behind this HIV-associated 
immune activation. A so-called “leaky gut syndrome” hypothesis proposes that massive loss 
of CD4+ T cells in the GALT may affect the protective barrier of the intestinal mucosa, 
allowing bacterial toxins such as lipopolysaccharide (LPS) to enter the bloodstream [25]. 
This “microbial translocation” could in consequence induce a pathological over-activation of 
both the innate and adaptive immune system. Another hypothesis puts more emphasis on 
intrinsic regulation of type I interferon (IFN) [26]. It has been shown indeed that patterns of 
type I IFNs produced by plasmacytoid DCs (pDCs) are different in non-pathogenic SIV 
infections of natural hosts (like sooty mangabeys, African green monkeys and mandrills) 
and pathogenic SIV infections of rhesus macaques. High and robust type I IFN responses 
are observed in natural hosts during acute infection. Expression of type I IFNs is, however, 
down-regulated during the chronic infection phase. By contrast, the type I IFNs are 
persistently produced in SIV infected rhesus macaques [27]. Sooty mangabeys, the natural 
hosts of SIV, show no immune activation and rarely progress to AIDS, despite high levels of 
virus replication and severe CD4+ T cell depletion in the GALT. In contrast, rhesus 
macaques, infected with the same or closely related SIV, progress to AIDS [28].  
Another enigma remains the role of CD25 and forkhead box (FOX) P3 expressing regulatory 
CD4+ T (Treg) cells. On the one hand, they may suppress chronic immune activation. On the 
other hand, they could undermine the effective T cell responses [29]. It has been shown that 
the number of Treg cells increases in the GALT, but not in the peripheral blood, during HIV 
infection in untreated individuals [30]. Whether this accumulation of Treg cells delays 
disease progression by inhibition of immune activation or increases the susceptibility of the 
gastrointestinal tract to opportunistic infections remains a matter of debate [29].  
2.2. HIV-specific humoral immune response 
The humoral immune response is mediated by antibody producing B cells (figure 1). In 
general, by preventing infections of the host cells, virus-specific antibodies play an 
important role in the control of many viral infections [31]. This arm of the adaptive immune 
system is activated after uptake of viral proteins by antigen presenting cells (DCs, 
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macrophages and B cells) that digest the proteins into small peptides and present them on 
MHC II molecules to CD4+ T helper (Th) cells. Specifically activated Th2 cells that produce B 
cell stimulating cytokines (including IL-4, IL-5, IL-6, IL-10, TGF−β) will activate naive B cells. 
The latter are recognized by specific epitopes or intact virus through their surface IgM and 
promote B cell differentiation into plasma cells producing large amounts of IgG, IgA, IgE 
antibodies and memory B cells. During HIV-1 infection antibodies against gp120, gp41, the 
nucleocapsid (p24) and the matrix (p17) arise few weeks to several months after infection. 
This process is commonly referred to as seroconversion.  
 
 
Figure 1. Overview of the adaptive immune responses after virus recognition by antigen presenting 
cells. Virus antigens are presented by dendritic cells and B cells to T cells. Infected cells present peptides 
together with MHC I molecules on the plasma membrane. The peptide-MHC I complex is recognized 
by precursor cytotoxic CD8+ T lymphocytes (CTLs). Th1 cells, induced by antigen presenting cells, 
produce IL-2, IFN-γ, and TNF-α. This results in activation and differentiation of the precursor CTLs 
into memory or effector CTLs. Effector CTLs can directly kill infected cells by the production of 
perforines and granzymes. Activated Th2 cells, also induced by antigen presenting cells, produce B cell 
stimulating cytokines (including IL-4, IL-5, IL-6, IL-10, TGF−β) that activate naive B cells. This 
facilitates/induces B cell differentiation into memory B cells and plasma cells that produce large 
amounts of IgG, IgA, IgE antibodies that prevent further virus infection. Ab: antibody, Ag: antigen, 
APC: Antigen Presenting Cell, DC: Dendritic Cell, IL: Interleukin, TCR: T Cell Receptor, Th: CD4+ T 
helper cell. 
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The virus neutralization is characterized by the interaction of specific antibodies with the 
viral envelope spikes. This interferes with virus attachment or viral entry in target cells and 
results in the inhibition of infection. Only a minority of anti-HIV Env antibodies, at any 
time, exerts immune pressure by autologous neutralization. However, the virus easily 
mutates and readily escapes from these potentially protective immune responses [32]. 
During the chronic course of infection only 20% of the infected individuals will generate 
broadly neutralizing antibodies (bNAbs) having the ability to neutralize heterologous 
viruses [33]. In addition to classical neutralization, antibodies can attach to HIV infected 
cells and kill them via antibody dependent cellular cytotoxicity (ADCC) mediated through 
their Fc moiety and natural killers cells (NK) [34, 35].  
2.3. HIV-specific cellular immune response 
The cellular immune response is the other arm of the adaptive immune system (figure 1) 
and it is crucial to combat viral infections. CD8+ cytotoxic T lymphocytes (CTLs), which 
eliminate infected cells, play a key role in this process. The initial step involves processing of 
intracellular antigens by the proteasome. The resulting peptides are then presented together 
with MHC I molecules on the membrane of infected somatic cells. The peptide-MHC I 
complex is recognized by precursor cytotoxic CD8+ T lymphocytes (CTLs). Also in that case 
a CD4+ T cell help, induced by antigen presenting cells, is crucial. In this case so-called Th1 
cells, producing IL-2, IFN-γ, and TNF-α, activate and differentiate the CTLs into memory or 
effector CTLs. Effector CTLs can directly kill infected cells by the production of perforines 
and granzymes (figure 2) [36]. Alternatively, CTLs can induce apoptosis of the infected cells 
after interaction of Fas ligand on CTLs with Fas receptor on infected T cells [37]. CD8+ T cells 
also display a non-cytotoxic antiviral activity involving several cytokines, chemokines and a 
yet unidentified soluble CD8+ cell antiviral factor (CAF) [38].  
 
Figure 2. HIV-induced T cell responses. HIV specific CD8+ effector cells produce chemokines and 
cytokines in order to eliminate infected cells. CD4+ T helper cells help to stimulate both dendritic cells 
and CD8+ T-cells to maintain a CD8+ T-cell memory response. HIV interferes with this supportive 
function of CD4+ T-cells. 
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The first T cell responses during HIV infection arise when the viraemia peak is approached 
and reach maximum 1-2 weeks later. In non-controllers, the virus  evades the CD8+ 
mediated T cell response by introducing mutations in CTL epitopes [39], by Nef-mediated 
down-regulation of MHC I and by influencing cytokine production and T-cell signaling [40]. 
Since an optimal CD8+ T cell response, similar to the B cell response, depends on help of 
CD4+ T lymphocytes, the deterioration of CD8 mediated viral control is also related to the 
weakening of CD4+ T cell function [41, 42]. 
There are many indications that HIV-specific CD8+ T cell responses are responsible for at 
least partial VL control. In the macaque model, depletion of CD8+ T cells during SIV- 
infection resulted in an increased viral load [43, 44]. In HIV-infected human subjects, who 
initially control the virus, escape mutations in specific CD8+ T cell epitopes were responsible 
for the loss of control and increase in VL [45, 46].  
3. Correlates of protection 
To date no definite biological markers have been unambiguously shown to correlate with 
patients’ ability to control HIV infection by suppressing virus production and eliminating 
infected cells. Defining these factors would be crucial for the development of preventive and 
therapeutic vaccination strategies. For that reason, research groups focusing on preventive 
vaccines carefully study individuals that can avoid infection (exposed seronegatives) or 
partly control the virus load without the need of HAART. 
3.1. Natural resistance and genetic factors of the host 
Individuals that have the homozygote deletion Δ32 in co-receptor CCR5 are largely resistant 
to HIV-1 infection [47]. It has been recently reported that an HIV patient, who received 
CCR5 Δ32/Δ32 stem cells for transplantation, remained without viral rebound for several 
years [48, 49]. 
Certain intracellular molecules, expressed by the host, can at least partly protect against 
cellular infection or virus release. The most important factors identified so far are 
APOBEC3G, APOBEC3F, TRIM5α and tetherin. APOBEC3G is a cytosine deaminase that 
incorporates adenosine instead of guanosine during synthesis of the viral DNA, which 
results in defective proviral DNA [50]. In addition APOBEC3G promotes natural killer cell-
mediated lysis [51]. Individuals expressing large amounts of APOBEC3G have lower viral 
loads during acute infection phase [52]. TRIM5a binds to the viral capsid, blocking 
replication early in the viral life cycle [53]. Tetherin interferes with the virion release by 
attaching the mature virions to each other and to the host membrane [54]. 
Certain polymorphisms in the human leukocyte antigen (HLA type) and T or NK cell 
receptor can affect the cellular HIV-specific immune responses. It has been shown that 
human leukocyte antigens B*27, B*57 and B*58 are associated with better control of HIV-1 
and slower disease progression [55-57]. Interestingly HLA B*57 also plays a role in the 
innate protective immune responses, acting as a natural ligand for inhibitory killer 
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immunoglobulin-like receptors (KIRs). KIR3DL1 and KIR3DS1 are also associated with 
delay in disease progression [58, 59]. 
3.2. Suggested immune correlates 
High and broadly neutralizing antibody titers at the port of the virus entry are likely 
essential to prevent (new) infections of host cells. Indeed high levels of HIV-neutralizing IgA 
were detected at mucosal surfaces of some exposed seronegative individuals [60-62]. 
Moreover, in several models of transmission, passive immunization with neutralizing 
monoclonal antibodies could protect macaques from infection. In contrast, once infection 
has been established, neutralizing antibodies seem to be unable to control the virus spread 
[63]. In order to eliminate infected cells, strong CD8+ T cell responses seem to be of 
importance. As already discussed, most infected individuals show strong CD8+ T cell 
responses in reaction to the first viraemia peak, resulting in a decline of the viral load in 
early infection. Unfortunately, in most cases (except for elite controllers) these responses are 
not able to maintain full control, mainly due to iterative immune escape [39] and chronic 
immune activation [23], ultimately resulting in T cell exhaustion [64]. In contrast, HIV-
specific CD8+ T cells preserve their function and new effective CD8+ T cell responses can 
arise against viral escape variants in elite controllers [55]. Additionally, a strong avidity of 
the T cell receptor for the epitope-MHC-I-complex has been shown to promote 
polyfunctional CD8+ T cells [65] and to initiate more rapid lysis of the target cell [66, 67]. 
Furthermore, the presence of polyfunctional CD8+ T cells, that have the capacity to exert 
different effector functions by producing IFN-γ, TNF-α, IL-2, MIP-1β, perforines and/or 
granzymes and to proliferate upon antigen stimulation, has been associated with the 
“controller” status [68, 69]. Another important observation came from the study of 
Geldmacher and colleagues who reported that responses directed against Gag epitopes are 
dominant and potentially protective in long term non progressors  and elite controllers [70]. 
One of the reasons for this observation could be escape mutations, in particular HLA-
restricted epitopes of Gag, that come at a cost of great loss in viral fitness [71-73]. 
As already explained, maturation and differentiation of CD8+ T cells into functional memory 
and effector subsets are also dependent on functional CD4+ T helper cells. The remaining 
CD4+ T cells, after massive depletion during acute infection, need to be polyfunctional by 
producing at least both IFN-γ an IL-2 in order to proliferate upon antigen stimulation [41] 
and provide help to CTL. This Th1 function is impaired in HIV non-controllers [74]. 
Unfortunately, none of these factors can truly predict protection against HIV infection [75]. 
Therefore, at present it seems wise to conclude that all potential correlates (table 1) should 
be taken into account while designing HIV therapies. This includes the preservation of 
functional Th1 HIV-specific CD4+ T cells and the availability of central memory and memory 
effector HIV-specific CD8 T cells, with strong avidity for particular difficult-to-mutate 
epitopes. In addition also a broad functional activity, including production of several 
effector cytokines and lytic factors are important to result in high and broad HIV-
suppressive immune responses [75].  
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Level of protection Suggested correlates of protection
Viral factors Deletion in Nef [76] 
Host genetic factors CCR5 D32/D32 [48, 49] 
Host restriction factors High levels of antiviral fator APOBEC3G [51, 52] 
High production of TRIM5α [53] 
Up-regulation of tetherin [54] 
HLA types B*27, B*57, B*58 [55, 56] 
KIR3DL1, KIR3DS1 [58, 59] 
Humoral immunity Neutralizing Abs: IgA antibodies at the mucosal surfaces [60-63] 
Cellular immunity Polyfunctional T cells [66, 69] 
Proliferative CD4+ and CD8+ T cells [68, 70] 
  Avidity of HIV specific T cell responses [65, 66, 74] 
Table 1. Suggested correlates of protection. 
4. Vaccination strategies against HIV-1 
Many infection-related hurdles complicate the development of an HIV vaccine. These 
include the high genetic variability, the potential of cell-to-cell transmission and other 
evasion strategies such as down-regulating MHC I in infected cells and latency of the virus 
[77]. In addition, correlates conferring protection against HIV remain to be established. A 
number of potential markers have been suggested to prevent or control HIV infection. These 
comprise: production of high titers of neutralizing antibodies with broad specificities, 
concomitant HIV-specific activation of CD4+ and CD8+ T cells, polyfunctional T cell 
responses (production of several immune mediators by the same T cell) and induction of 
long- term memory cells [78]. 
4.1. Prophylactic vaccines  
Prophylactic vaccines rely on the production of antibodies that bind to free virus particles 
thereby preventing viral entry into host cells (defined as neutralization) and thus block 
infection. Vaccines are designed to mimic natural infections, by using live-attenuated virus 
(measles, mumps), chemically inactivated virus (polio) or recombinant subunits of the virus 
(Hepatitis B). There is circumstantial evidence that neutralizing antibodies could play a role 
in the protection against HIV. HIV-neutralizing IgA antibodies have been isolated in 
frequently exposed individuals, who remained uninfected [62, 79]. In addition, passive 
immunization with several HIV neutralizing IgG monoclonal antibodies protects macaques 
against infectious SHIV (simian immune deficiency virus with an HIV envelope) [80, 81]. 
Although attenuated SIV vaccines provided some level of protection against super-infection 
in macaques, attenuated HIV is considered too risky to be ever tried in humans [82]. 
Therefore, much effort has been invested in the development of subunit vaccines that could 
elicit production of neutralizing antibodies. It should be taken into account that broadly 
neutralizing antibodies (bNAbs) that inhibit also heterologous viruses in vitro, can be 
detected in 20% of naturally infected individuals. This implies that the production of these 
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antibodies is not sufficient to provide full protection against established HIV, but could still 
be efficient in prevention of cell-free transmission. The most important reason why it is 
difficult to induce bNAbs is the extreme variability of HIV Env antigenic epitopes. 
Moreover, the virus is shielded by non-immunogenic glycans, which hinder binding of 
antibodies to the envelope proteins [83, 84]. Due to these problems, prophylactic vaccine 
trials in humans have failed to elicit protection. The only exception till now is the recent 
Thai vaccine trial (RV144).  
Nevertheless neutralizing antibodies with activity against easy-to-neutralize so-called “Tier 
1” viruses have been induced in a number of animal trials, but these antibodies failed to 
broaden and faded rapidly, even upon repeated heterologous boosts [85]. The failure to 
induce high titers of NAbs moved the field towards strategies aiming at stimulating 
polyfunctional and sustained CD4+ T help responses [69] to support high quality cytotoxic T 
cells (both central memory and effector memory). These cells would be necessary to rapidly 
eliminate infected cells, if antibodies fail to prevent cellular infection [86, 87]. This “second 
line prevention” hypothesis was further supported by the observations that HIV-specific 
CD4+ and/or CD8+ T cells as well as particular human leukocyte antigen (HLA) class I 
markers, and not antibodies, correlate with resistance to HIV in some highly exposed 
seronegative children (potential vertical transmission) [88] or women (potential heterosexual 
transmission) [89-91]. 
In this connection, current HIV vaccines are also aiming at the induction (prophylactic field) 
or enhancing (therapeutic field) of HIV specific T cell responses. Such vaccines would elicit 
or boost HIV specific cytotoxic T cells (CTLs) to eliminate infected cells and CD4+ T cells, 
which can help to induce and maintain B cell and CD8+ T cells responses [92]. Several 
strategies are currently under investigation to establish effective T cell responses in either a 
preventive or therapeutic setting either based on protein [93, 94] or peptide [95] 
vaccinations, virus like particles (VPLs) [96], DNA vaccination using viral vectors [97, 98], 
prime-boost vaccinations [99, 100] or DC-based vaccines [101-109]. 
4.2. Viral vaccine delivery 
Whereas the use of live attenuated HIV is considered to be unsafe for the use in humans, the 
development of vaccines based on HIV-inactivated with formalin is compromised by the 
fact that the antigenicity of the envelope gets lost. Milder formalin treatment of the virus, 
followed by heat-inactivation has been shown to circumvent this hurdle and induce modest 
neutralizing antibodies titer in non-human primates [110].  
During the last decade, a variety of vaccines was designed using (plasmid) DNA/RNA 
vaccine candidates for priming followed by live vectored recombinant vaccines for 
boosting, some of which have already been tested in advanced stages of clinical trials [111, 
112]. We will highlight here some of the specific characteristics of viral vectors, which 
have been used in preclinical and early clinical preventive vaccinations against SIV and 
HIV, respectively. 
 
“Wrapped Up” Vaccines in the Context of HIV-1 Immunotherapy 37 
Adenoviruses, poxviruses and lentiviruses are the most frequently used viral vector 
systems. The major advantages of these vectors are the high transduction efficiency 
resulting in high level expression of the encoded protein and the possibility to target specific 
cells achieved by altering the viral tropism (e.g. by pseudotyping with envelope or counter 
receptors of another virus) [113, 114]. Major drawbacks are the high risk of insertional 
mutagenesis, high production cost of large amounts high-titered viral stocks and a limited 
size of nucleic acids that can be packed [113, 114]. The first trial of a preventive HIV vaccine 
that was designed to elicit a strong cellular immune response was the STEP trial done by 
Merck. It involved immunization of almost 3000 healthy uninfected volunteers with three 
recombinant adenovirus serotype-5 (rAD5) vectors, Ad5-gag, Ad5-pol and Ad5-nef. 
Unfortunately, it failed to induce protection against infection [115, 116]. Moreover, the 
vaccine increased the rate of HIV infection in individuals with pre-existing immunity to 
adenoviruses [117]. The exact mechanism that underlies this phenomenon remains to be 
elucidated, but it has been suggested that the activation of pre-existing vector specific T cells 
may have increased numbers of HIV target cells. This might be avoided by the use of less 
prevalent adenovirus serotypes (e.g. Ad11, Ad24 or Ad35) instead of the Ad5 vector in 
designing future HIV vaccines [118, 119]. 
Alternatively, poxvirus-based vectors should be taken into account since they do not pose 
any problems with pre-existing immunity. In addition, they are used as highly attenuated 
vaccinia virus strains. Three of the best characterized highly attenuated pox vectors are the 
recombinant viral canary pox vectors such as the highly attenuated vaccinia virus strain 
ALVAC [120], the recombinant modified vaccinia Ankara (MVA) vectors [121-123] and 
canarypox-derived NYVAC [120, 124, 125]. Recombinant pox vectors, encoding HIV 
antigens, have been shown to be safe in humans and to induce HIV specific immune 
responses. No protection against HIV infection has been achieved with the exception of the 
preventive RV144 phase III clinical trial. In this clinical trial, involving 16 000 uninfected 
individuals, a canary pox vector coding HIV Gag and Env was used as prime immunization 
followed by a recombinant Env gp120 protein boost (RV144). A 31% efficacy of protection 
against HIV infection was demonstrated after three years [126]. Very recently, Barouch et al. 
reported that rhesus monkeys, receiving heterologous vector regimes (adeno with MVA), 
were protected with an efficacy of 80% after SIV challenges [127]. 
Another type of vectors that could avoid the pre-existing immunity issue is based on 
lentiviruses. These vectors have been explored extensively in the field of gene therapy since 
they efficiently transduce non-dividing cells, such as DCs [128, 129], and promote long term 
antigen expression [130]. Lentiviral vector vaccines have been shown to induce both high 
short term and long-term anti-HIV immune responses in mice [131, 132]. Even in the 
absence of circulating CD4+ T cells, induction of specific CTLs was obtained [133]. Despite 
reassuring safety and tolerability results in a phase I clinical trial [134], the major concern 
remains the risk of insertional mutagenesis [135]. Attempts to overcome this risk, have led to 
the design of self-inactivating vectors, vectors with targeted integration and non-integrating 
vectors [135]. 
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Replicating and persistent recombinant cytomegalovirus (CMV) vectors have recently been 
shown to be a promising system in rhesus macaques [136]. Prophylactically vaccinated 
animals maintained CD4+ and CD8+ T effector memory (TEM) cell responses, regardless to 
pre-existing CMV immunity, and were more resistant to challenge than the control group 
even in the absence of neutralizing antibodies [137]. The authors suggest that TEM responses 
are crucial in the protection against HIV infection after sexual exposure. This is obviously 
also the scope of HIV immunotherapy where sustained effector and memory T cells can 
eliminate infected cells. 
Virus-like-particles (VLPs) have recently emerged as novel delivery systems. They contain 
envelope and core proteins from SIV/HIV in their native structure. These pseudo-virions are 
produced in baculovirus or vaccinia virus expression systems where Gag and Env proteins 
from HIV or SIV are co-expressed and spontaneously assembled. The immunogenicity of 
these vaccines was only modest in non-human primates [96], however, efficiency was 
greatly improved when combined with a HIV DNA vaccine prime [138].  
Safety concerns and difficulties related to repeated administrations of viral vectors that may 
evoke dangerous immune reactions are the most important bottlenecks in regard to clinical 
application in humans. To improve the general safety profile and circumventing the 
drawbacks inherited to viral delivery, well-defined particulate vaccines have emerged as 
promising candidates in the field of vaccine development. 
5. HIV Immunotherapy with DC-based vaccines 
5.1. Therapeutic vaccines 
Since the introduction of HAART, HIV-1 infection has evolved into a chronic but treatable 
disease. Although HAART suppresses viral replication and partially reconstitutes both CD4+ 
T cell numbers [139] and T cell immune responses to opportunistic infections, it cannot 
restore effective HIV specific T cell responses [140], resulting in a rapid rebound of HIV-1 
replication upon treatment interruption [141]. This implies that infected individuals are 
bound to lifelong treatment, imposing a high burden in terms of adherence, costs and the 
risk of drug related metabolic disorders [142]. Therefore, therapeutic vaccination has 
emerged as an option to boost and improve the cellular immune responses in infected 
individuals [143]. This concept is supported by increasing evidence that strong HIV-1 
specific CD4+ helper T cells and CD8+ CTLs are responsible for viral control both in 
macaques [144] and humans [145]. During acute infection CD8+ T cell responses contribute 
to control of the initial viraemia peak. However, in most infected subjects, this CD8+ T cell 
response loses its efficacy during chronic infection. This is due to a high mutation rate of the 
virus, the absence of proliferative and highly functional CD4+ T cells [145, 146] and the 
appearance of impaired or apoptotic HIV-specific CD8 T cells [147]. Clearly, the major 
challenge for therapeutic vaccination is to elicit strong CD4+ and CD8+ responses that would 
allow stopping of HAART. In vitro modulation of DCs to efficiently present target antigens 
to elicit cellular immune responses has been shown to be a promising strategy in cancer 
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immunotherapy [148], which constituted a model for development of similar HIV 
immunotherapies. 
5.2. Dendritic cells 
DCs are the sentinels of the immune system, bridging innate and adaptive immunity, in 
response to pathogens crossing the mucosal or dermal barrier. Immature DCs (iDCs) 
continuously sample their environment and take up autologous and foreign antigens [149]. 
They undergo maturation in response to signals that originate from pathogen-associated 
molecular patterns (PAMPs). These PAMPs activate a set of pattern recognition receptors 
(PRRs) such as Toll like receptors (TLRs), nucleotide-binding oligomerization domain 
(NOD)-like receptors (NLRs), C-lectin receptors (CLRs) and retinoic acid-inducible gene 
protein (RIG)- like receptors (RLRs). Triggering of PPR results in an increased expression of 
major histocompatibility complex I and II (MHC I and MHC II), co-stimulatory molecules 
(CD80 and CD86) as well as secretion of T cell stimulatory cytokines (e.g. IL-12). During this 
maturation process DCs lose their ability to take up antigens and chemokine receptors (e.g. 
CCR7) are up-regulated in order to promote their migration to lymph nodes. Mature DCs 
process endogenous antigens via proteasome into 8-9 amino-acid peptides which are then 
loaded on MHC I and presented to CD8+ T cells. Exogenous antigens are processed via the 
endolysosome into longer peptides to be load onto MHC II for presentation to CD4+ T cells. 
The capacity of DCs to present exogenous antigens also via MHC I pathway (i.e. cross 
presentation), distinguishes them from other APCs, such as macrophages and B cells. To 
stimulate effective T cell responses, peptide-MHC complex on DCs should interact with T cell 
receptors (TCR). This is accompanied by binding of co-stimulatory molecules on DCs with 
CD28 present on T cells (figure 3). Finally, produced cytokines determine the differentiation of 
the effector cells into Th1, Th2 or CTL [150]. The latter is achieved after DCs’ licensing by the 
interaction of CD40 on the mature DCs with CD40L expressed on CD4+ T cells. IL-4 secretion 
promotes CD4+ Th2 cells, stimulating the production of antibody producing B cells. IL-12 
promotes CD4+ Th1 cells, providing help to CTL to kill infected cells. Secretion of IL-10 has a 
negative impact on Th1 or Th2 cells and induces immune tolerance. Licensed DCs also induce 
differentiation of CD8+ T cells into CTL via peptide-MHC I complex and promote survival of 
CD8+ T cells via co-stimulation through CD137L (4-1BBL) [151]. 
Roughly five DC subsets can be distinguished [152]. Classical or tissue resident DCs are 
located in lymphoid organs such as spleen and lymph nodes. Migratory DCs, found in non-
lymphoid organs such as skin, intestines and lungs, sample their environment and migrate 
to lymph nodes to present tissue derived antigen to T cells. Langerhans cells reside in the 
multi-layerd epithelium of the skin, oral and genital surfaces. Plasmacytoid DCs (pDCs) and 
myeloid or monocyte-derived DCs may be present in various tissues, yet they mainly 
circulate in the blood. pDCs are known as major producers of type I interferons (IFNs) in 
response to virus-associated molecules such as single-stranded (ss) RNA and unmethylated 
cytosine-phosphate-guanine (CpG)-rich DNA that trigger TLR7 and TLR9, respectively 
[153]. Myeloid DCs represent the major fraction of APCs in the blood that responds to TLR 
ligation by producing IL-12 [154]. Noteworthy, the APC function of DCs is impaired by 
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HIV, which could contribute to the dysfunction of HIV specific T cell responses since 
maturation of DCs and IL-12 secretion are diminished, thereby suppressing T cell responses 
[155]. HIV-infected DCs preferably secrete IL-10 thus limiting T cell proliferation and 
activation and rather induce tolerance [156]. HIV-1 infected DCs also act as a Trojan horse to 
infect new T cells by promoting tolerance of T cells to HIV-1 [157]. 
 
Figure 3. Differentiation process of dendritic cells. Immature DCs take up antigens. Activation of PPRs 
results in the differentiation towards mature DCs. The co-stimulatory molecules (B7-1, and B7-2) are 
overexpressed and the expression of the lymph node homing receptor CCR7 is induced. Mature DCs 
migrate to the draining lymph node, where they present antigens to cognate CD4+ T cells. Cross-linking 
CD40 on the DCs by CD40L expressed on the antigen-activated CD4+ T cell, induces the mature DCs to 
differentiate further, a process known as licensing. Licensed DCs up-regulate additional cell surface 
proteins, such as CD137L. The licensed DCs now present antigens to cognate CD8+ T cells. CD137L–
mediated co-stimulation through CD137 on the antigen-activated CD8+ T cells enhances the survival and 
proliferative capacity of the activated CD8+ T cells.  
5.3. HIV-1 antigen loaded dendritic cells tested in clinical trails 
To obtain a large population of DCs to be used in immunotherapy, DCs are derived from 
blood monocytes that are cultured in the presence of granulocyte and macrophage colony 
stimulation factor (GM-CSF) and IL-4 [158, 159]. Various approaches for loading DCs with 
antigens have been applied. They include the use of inactivated virus [104, 160], 
recombinant viral proteins [107, 161-163], peptides [101, 164], DNA [165-167] and mRNA 
[168-172]. After loading, DCs are matured using various maturation cocktails composed of 
cytokines (such as type 1 (α,β) or type 2 (γ) interferons, TNF-α, IL-6) prostaglandines (PG), 
TLR ligands, T cell derived products (CD40L) or small interfering RNA (siRNA) against 
suppressors of cytokine signaling (SOCS)-1 [98, 151].  
To this date at least ten DC-based immunotherapeutic vaccine trials (table 2) have been 
tested in infected individuals (recently reviewed by García and Routy [173]. Kundu et al. 
were the first to perform a human clinical trial, in which treatment-naïve HIV infected 
individuals were vaccinated with protein or peptides pulsed autologous DCs [107]. The 
vaccine was well tolerated and resulted in an increase of HIV specific CD8+ T cell response 
in 3 out of 6 individuals, but no effect on viral load was observed. Three other clinical trials 
tested peptides pulsed DCs [101, 105, 106]. In two of these trials an increase in HIV-specific 
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T cell responses in the absence of virological responses was shown [101, 105], whereas in the 
third study a transient decrease in viral load was found in 50% of vaccinated individuals 
[106]. Lu et al. were the first to demonstrate in vivo that a vaccine made of autologous 
monocyte-derived DCs, pulsed with autologous, aldithriol-2-inactivated HIV-1 was capable 
of inducing HIV-1-specific T cell responses. Moreover, there was an 80% decrease in plasma 
viral load levels over the first 112 days after vaccination. A prolonged suppression of viral 
load (of more than 90%) was seen for at least 1 year after vaccination in 8 out of 19 
vaccinated patients. This suppression of viral load correlated with HIV-1-specific IL-2 and 
IFN-γ expressing CD4+ T cells and with HIV-1 Gag-specific perforin-expressing CD8+ 
effector cells [108]. Unfortunately, the lack of a control group does not allow a proper 
evaluation of the results obtained. The group of García et al. performed two clinical trials 
with autologous DCs pulsed with heat-inactivated virus [103, 104]. In a double blind 
placebo controlled study with a similar setup as Lu et al., García et al. observed a small but 
significant decrease in viral loads for at least 48 weeks, concomitant with a weak increase in 
HIV-1 specific T cell responses in therapy naïve HIV infected individuals [103]. Another 
study performed by the same group in HAART treated patients showed a lengthening of 
the rebound after therapy interruption and a moderate increase in HIV specific T cell 
responses [104].  
 
Form of 
antigen 
Vaccine strategy Subjects Clinical trial outcome 
Inactivated 
virus 
DCs pulsed with 
autologous AT2 
inactivated virus (109) 
Untreated 
patients (n= 18) 
Suppression of viral load was 
correlated with HIV specific IL-2 
or IFN-γ producing CD4+ T cells 
and perforin producing CD8+ 
effector T cells. [108] 
DCs pulsed with 
autologous heat 
inactivated virus (106) 
HAART treated 
patients  followed 
by therapy 
interruption 
(n=18)
Lengthening of viral rebound 
correlated with numbers of HIV-
specific proliferative CD4+ and 
CD8+ T cells. [104] 
DCs pulsed with 
autologous heat 
inactivated virus (109) 
Untreated 
patients (n= 18) 
Inverse correlation between 
decrease in viral load and HIV-
specific T cell responses. [103] 
Peptides DCs pulsed with Gag, 
Pol and Env peptides 
Untreated 
patients (n= 6) 
In 3/6 cases Env-specific and 
proliferative immune responses 
were observed. [107] 
DCs pulsed with HLA 
A*0201 binding epitopes 
in Gag, Nef and Env 
HAART treated 
patients  followed 
by therapy 
interruption (n=4)
In 2/4 patients moderate CD8+ T 
cell responses were observed. No 
lower viral setpoints after 
therapy interruption. [105] 
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Form of 
antigen 
Vaccine strategy Subjects Clinical trial outcome 
DCs pulsed with HLA 
A*0201 binding epitopes 
in Gag, Pol and Env 
HAART treated 
patients  (n=18) 
Increase in CTL responses against 
vaccine epitopes. [101] 
DCs pulsed with HLA 
A*0201 binding epitopes 
in Gag, Pol, Env, Vpu 
and Vif and Th epitopes 
in Gag and Env 
Untreated 
patients (n= 12) 
Generation of new T cell 
responses despite high viral 
loads. [106] 
DNA ALVAC pulsed DCs  vs 
AlVAC alone 
HAART treated 
patients  followed 
by therapy 
interruption  
(n=29)
No differences in T cell responses 
against HIV antigens. Did not 
lower VL setpoint after therapy 
interruption. [102] 
ALVAC-Remune HAART treated 
patients followed 
by therapy 
interruption 
(n=48) 
No lowering of viral setpoint 
after vaccination, but VL rebound 
was delayed. [177] 
mRNA Ex vivo electroporated 
DCs with mRNA 
encoding CD40L and 
autologous HIV proteins 
(Gag, Ref, Nef, Vpr) 
HAART treated 
patients  (n=10) 
HIV specific proliferative 
immune responses preferentially 
targeted to CD8+ T cells. 
Correlation with viral control 
during therapy interruption. 
[109] 
Ex vivo electroporated 
DCs with mRNA and 
autologous HIV proteins 
(Gag, Tat, Rev, Nef)  
HAART treated 
patients (n=6) 
Breadth of IFN-γ response and T-
cell proliferation were correlated 
with CD4+ and CD8+ 
polyfunctional T-cell responses. 
Autologous CD8+ T cells 
inhibited HIV superinfection in 
vitro. [176] 
Ex vivo electroporated 
DCs with mRNA and 
autologous HIV proteins 
(Tat, Rev, Nef)  
HAART treated 
patients followed 
by therapy 
interruption 
(n=17) 
Induced or enhanced CD4+ and 
CD8+ T cell responses specific for 
the vaccine antigens. [175] 
Table 2. Overview of therapeutic DC-based clinical trials. 
Nucleic acids are also used as a source of antigens in DC-based immunotherapies. Phase I 
and II clinical trials were conducted to evaluate the potential of a canarypox HIV-vaccine 
(ALVAC), containing DNA encoding Env, Gag as well as parts of Nef and Pol to either 
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directly vaccinate HAART-treated patient or ex vivo load autologous DCs. The results 
obtained did not demonstrate clear differences in the immunological or virological outcome 
and a control group was lacking [102]. In a very recent study, DNA encoding HIV proteins 
was complexed with polymers and topically administrated with a patch method named 
DermaPrep [174]. The results showed that vaccination induced new HIV-specific immune 
responses in HAART treated patients. Moreover, a better control of viral replication during 
treatment interruption was observed [167]. DCs loaded with mRNA have also been tested in 
clinical trials. Routy et al. reported the results of a trial in which HAART-treated patients 
received autologous DCs ex vivo electroporated with mRNA encoding autologous HIV 
sequences and CD40L [173]. This pilot study showed CD8+ T cells specific for the presented 
HIV antigen were preferentially targeted. Two other clinical trials employing autologous 
DCs electroporated ex vivo with mRNA encoding Tat, Rev, Nef and Gag were recently 
concluded [175, 176]. Both studies showed that vaccine-specific CD4+ and CD8+ T cell 
responses were enhanced. In one study vaccinated individuals interrupted treatment. Six 
out of 17 individuals remained off therapy 96 weeks after cessation [175]. 
One should keep in mind, however, that ex vivo manipulation of DCs is a complex 
personalized vaccination procedure, which prevents its accessibility to large numbers of 
patients. Therefore, there is a constant need for new approaches that could target DCs 
directly in vivo. In the following paragraphs we will discuss various non-viral delivery 
approaches which promote antigen uptake by DCs and induce potent immune responses. 
6. The way forward: Antigen delivery by non-viral carriers 
Even though viral vectors are generally considered more efficient, non-viral delivery 
vehicles receive increasing attention since they are safer, more versatile, easier to prepare 
and hence more accessible for up-scaling [178]. In addition, they allow delivery of larger 
quantities of antigens. Importantly, encapsulation protects antigens from their environment 
and therefore permits a prolonged release of antigens in tissues or particular cells [179]. 
The usual size of particulate vaccines, ranging from a few hundred nanometers to a few 
microns, is ideal for uptake by DCs [180]. Moreover, the nature of non-viral carriers 
allows their functionalization with moieties permitting specific targeting to DCs. 
Additionally they allow co-delivery of immunostimulatory molecules which can direct 
the immune system toward the humoral or cellular arm [181]. The simultaneous delivery 
of antigens and immune-stimulators to the same DC is a feature which has been reported 
to significantly augment the strength of the induced adaptive immune responses [182-
184]. In the following paragraphs we will discuss different lipid- and polymer-based 
carrier systems employed to deliver proteins and nucleic acids relevant for HIV-specific 
immunotherapy (table 3). 
6.1. Choice of antigen 
Peptides, proteins or nucleic acids (DNA or RNA) have been used as a source of antigen in 
the majority of therapeutic vaccination strategies. Each of them comes with specific 
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characteristics in terms of safety, stability, potential to cover antigenic variability, 
requirements for delivery and nature of the immune response induced [185]. Recombinant 
proteins or peptides utilized as subunit vaccines are safe and simple forms of antigens. 
However, their production at clinical grade quality is very expensive. As a consequence, 
only one or a few antigenic variants can be produced at an affordable price. Moreover, they 
are susceptible to pre-mature proteolytic degradation. Since DCs recognize them as 
exogenous antigens, they are preferentially presented in a MHC class II context [143] and to 
a lesser extent onto MHC I molecules via cross-presentation [180]. Therefore, they will not 
induce strong and broad CD8+ T cell responses, which are considered as a prerequisite for a 
therapeutic vaccine. These limitations can partially be resolved by their encapsulation. 
Encapsulation protects proteins and peptides from being prematurely degraded by 
proteolytic enzymes. Additionally, particulate antigen delivery favors cross-presentation 
thereby enhancing CD8+ T cell responses [186, 187]. In the context of HIV immunotherapy, 
however, the use of proteins as antigens is not ideal since HIV generates escape variants 
during the course of infection which remain present as a latent reservoir in cells [188]. With 
the technology available, it is not feasible to produce hundreds of variants of the same 
protein and include them in a therapeutic vaccine.  
 
Delivery 
vehicle 
Form of 
antigen 
Advantages Disadvantages 
PLA-PLGA 
particles 
Proteins FDA approved, induction of specific 
antibodies and Th1 cellular responses 
Harsh preparation 
process, expensive to 
upscale. 
Polyelctrolyte 
capsules 
Proteins, 
peptides 
Induction of both Th1 and Th2 
responses. Easy to tailor with 
immunostimulators. Stability and 
release kinetics correlate with a 
number of bilayers. 
Not (yet) FDA-
approved 
Polyplexes Nucleic 
acids 
Protect nucleic acids, facilitate escape 
from the endosomal compartment. 
Strong electrostatic 
interactions may 
hamper release of 
nucleic acids from the 
carrier 
Liposomes Proteins, 
peptides, 
nucleic 
acids 
Good protection of antigens, facilitate 
intracellular uptake. Induction of 
both Th1 and Th2 responses. 
Poorly immunogenic 
Lipoplexes Nucleic 
acids 
Protect nucleic acids, facilitate escape 
from the endosomal compartment. 
Might aggregation in 
the presence of  serum 
Table 3. Advantages and disadvantages of different non-viral delivery systems. 
Nucleic acids, such a plasmid DNA (pDNA) or messenger RNA (mRNA), encoding viral 
proteins, can more easily cover the wide range of viral quasi species [189, 190]. As compared 
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to pDNA, mRNA-based delivery may hold several advantages. First of all, mRNA is easier 
to engineer; there is no need for specific promoters and terminators to be present in the 
construct. Secondly, the synthesis of proteins encoded by mRNA is transient, which ensures 
a controlled antigen exposure [191]. Thirdly, in contrast to pDNA, mRNA does not need to 
cross the nuclear membrane to be effective and therefore offers the possibility to produce 
proteins in slow or non-dividing cells [192]. Furthermore, the use of mRNA excludes the risk 
of integration into the cell genome, eliminating possible insertional mutagenesis [189, 193]. For 
years, the application of mRNA has been hampered by a general believe that it is too labile to 
guarantee sufficient protein expression. Nowadays, however, mRNA vaccination strategies 
are being thoroughly investigated in the field of allergy [194, 195], cancer [193, 196-198] and 
HIV [109, 170, 171] immunotherapy. These studies mostly rely on the ex vivo electroporation of 
dendritic cells. We and others focus on complexing mRNA with cationic lipids and polymers 
(figure 4), which could protect mRNA. Moreover, we believe that complexing mRNA with 
cationic carriers might hold potential for their application in vivo. This approach could serve as 
an alternative for laborious ex vivo loading of DCs.  
 
Figure 4. Internalisation and intracellular trafficking of mRNA/cationic carrier complexes. Negatively 
charged mRNA is complexed with cationic carriers (lipid or polymer based). After endocytosis, 
complexes end up in endosomes, from where they should release their cargo mRNA into the cytoplasm 
to enable translation by ribosomes .Translated protein is either secreted or can directly be processed via 
proteaseome to be presented with MHC class I. Secreted protein can be taken up and promote 
presentation in a MHC class II way after cleavage in the endolysosomes. 
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6.2. Polymer-based antigen delivery systems 
Various polymers have been used to prepare nano- and micro- particles for antigen delivery. 
Here, we will focus on polymers that have shown to be promising in terms of 
immunotherapeutic vaccination. 
6.2.1. Polymers based on lactic acid (PLA) and glycolic acid (PLGA) 
The most studied polymers for antigen delivery in the context of vaccination are the 
biodegradable poly(D,L-lactide) (PLA) and poly(D,L-lactic-co-glycolic acid) (PLGA), which 
have been FDA approved for human use. These particles have mainly been evaluated for 
their potential to deliver proteins and peptides to DCs or macrophages with the aim to 
induce CD8+ cytotoxic T cell immune responses in the context of prophylactic vaccination. It 
has been demonstrated that PLGA particles are phagocytosed by APCs [199] and ensure 
prolonged antigen presentation by DCs [200]. Whereas empty PLGA particles do not 
influence the maturation status of DCs [201, 202], DC activation can be induced, if the PLGA 
polymer is employed to encapsulate TLR ligands (poly I:C, MPLA) or surface loaded with 
anti-CD40 antibodies clear activation of DCs was observed [203-205]. PLA particles carrying 
p24 protein have been shown to induce both mucosal antibody production as well as CTL 
responses [206, 207]. 
The main drawback of these polymers is that some antigens tend to aggregate during the 
encapsulation process. Moreover, the exposure of proteins to organic solvents, required to 
dissolve the polymer, makes them highly susceptible to denaturation leading to the loss of 
antigenic epitope recognition [208]. This can partially be overcome by adsorption of proteins 
on the particle surface [209, 210]. Additionally, a rather expensive up-scaling process and 
clean-up procedure to ensure sterile production constitute difficult obstacles [211]. Due to 
the harsh preparation process and the hydrophobic nature of PLGA and PLA, these carriers 
are not suitable for nucleic acids delivery [212-214]. 
6.2.2. Polyelectrolyte microcapsules 
Polyelectrolyte microcapsules (PeMCs) fabricated using a so-called layer-by-layer (LbL) 
technology are a relatively novel class of particles [215]. The process of their preparation is 
less harsh as compared to that of PLGA/PLA particles. A template containing an antigen 
and colloid nanoparticles is used as a sacrificial core. This core is coated with several 
bilayers of polymers of opposite charges. At the end of the procedure the template core is 
dissolved (figure 5). Since the encapsulation process is performed in a purely aqueous 
environment, minimal stress for a protein antigen is ensured. With appropriate choice of 
polymers, these particles can be fully biodegradable. De Koker et al. used ovalbumin as a 
model antigen and showed the benefit of antigen encapsulation in PeMCs to stimulate 
antigen presentation to T cells by murine bone marrow-derived DCs [186, 216].  
PeMCs containing p24 and poly I:C (TLR-3 ligand) have been shown to be promising as an 
HIV-1 immunotherapeutic vaccine. Both antigen and maturation stimulus could be 
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delivered in the same particle to DCs inducing maturation and stimulation of HIV-specific 
responses both in vitro and in vivo [184]. PeMCs were also used for the delivery of Gag-
peptides to APCs. These APCs could activate SIV-specific T cells in an ex vivo non-human 
primate model [217]. Immune responses could be further improved by sensitizing the 
PeMCs to enzymatic or reductive degradation upon cellular uptake, thereby assuring 
release of its cargo [218, 219]. 
PeMCs have been also employed to deliver pDNA [213, 220]. When considering their use for 
the delivery of mRNA, however, one should make sure that the preparation process is 
rigorously RNase-free, which might present a challenge.  
 
Figure 5. Preparation of polyelectrolyte microcapsule [186]. (a) In the first step an antigen (yellow) of 
interest is mixed with colloid nanoparticles (grey) to form a core template. (b) In the next step a layer of 
negatively charged polymer is deposited (blue). The non-adsorbed polymer is removed by washing. 
This is followed by applying a positively charged polymer (red) and another washing step. (c) When 
the desired number of polyelectrolyte layers is obtained, the core is dissolved. 
6.2.3. Polyethyleneimine-based polyplexes 
Polyethyleneimine (PEI) has been extensively used to deliver pDNA and siRNA to cells 
[221-223]. PEI consists of repeating units that contain two carbon atoms and a protonatable 
nitrogen atom. It exists in a linear or branched conformation (figure 6), both appearing in a 
broad range of molecular weights. PEI can efficiently bind pDNA to form so-called 
polyplexes. The linear form has been shown to release complexed pDNA more easily than 
the more stable branched form and thus results in higher transfection efficiencies [224]. The 
net positive charge of the polyplexes promotes their adhesion to the overall negative charge 
of the cellular membrane and facilitates their uptake. The protonatable units of PEI have a 
buffering capacity resulting in an influx of hydrogen ions into the endosomes upon polyplex 
uptake. Due to osmotic pressure thus building up, the endosomes are disrupted resulting in 
complex release into the cytosol [222, 225]. This mechanism of escape from the endosomes is 
called the proton sponge mechanism [226]. 
The group of Lisziewicz developed a therapeutic HIV vaccine, DermaVir, consisting of PEI-
mannose complexed with pDNA encoding several HIV-1 antigens [227]. The vaccine was 
administered using a patch (DermaVir Patch) and was meant to target Langerhans cells 
(LCs) [174]. The vaccine induced specific and long lasting immune responses resulting in  
reduced viral load in SIV-infected macaques [228]. The safety of the vaccine formulation and 
of the delivery method was demonstrated in a phase I clinical trial in humans. A phase II 
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clinical trial started in 2009 and aims at evaluating immunogenicity and efficacy of the 
vaccine in treatment-naïve and HAART-treated patients [229, 230]. 
 
Figure 6. Structures of polyethyleneimine: (a) Linear backbone. (b) Branched backbone. 
The main drawback of using PEI is its toxicity and non-specific interactions with cellular 
compartments. Another challenge is the aggregation of polyplexes in the presence of serum.  
Rejman et al. reported that complexes made of mRNA and cationic lipids are much more 
efficient in transfecting different cell lines than PEI polyplexes. The authors suggest that this 
was likely due to the strong affinity of the polymer to mRNA impeding the release of the 
nucleic acid from the complexes. [191]. Bettinger et al. tested the potency of different protein 
derivatives for the delivery of mRNA. They demonstrated that complexing mRNA with 
short peptides results in better transfection efficiencies, likely due to a weaker electrostatic 
interaction with the nucleic acid. It should be noted, however, that the expression levels 
obtained were in general very low [192]. 
6.3. Lipid-based antigen delivery systems 
6.3.1. Liposomes 
Liposomes are spherical entities consisting of a phospholipid bilayer and an aqueous inner 
compartment. They have been used for drug delivery to treat cancer and infectious diseases. 
Until now, few liposomal formulations reached the pharmaceutical market of the U.S.A. 
Liposomes have been also employed to deliver antigens [231]. Given the liposome structure, 
the antigen can be encapsulated in its core (hydrophilic molecules) or accommodated within 
the lipid bilayer (hydrophobic molecules) [232]. It has been demonstrated that the lipid 
composition determines the immunogenicity of liposomes. For example, the incorporation 
of cationic lipids has been shown to elicit elevated CTL responses compared to neutral or 
anionic lipids [233]. Liposomal particles can be modified with specific ligands or antibodies 
to improve the uptake or to enhance/skew the immune response. Virosomes or virus like 
particles that consist of functional viral envelope proteins, anchored in a lipid membrane, 
have proven to be promising vaccine candidates [234]. Importantly, antigenic proteins 
encapsulated in liposomes can elicit both MHC I and II mediated immune responses as 
demonstrated by Zheng et al. [235]. These authors showed that HIV-1 Gag, Pol and Env 
proteins delivered to DCs by cationic liposomes induced stimulation of HIV-1 specific CD8+ 
T cell responses. This was not observed when DCs were pulsed with the soluble proteins. It 
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has been reported recently that mice immunized with Gag protein encapsulated in 
liposomes functionalized with lipid A induced both humoral and cellular immunity [236]. 
Another strategy to increase immunogenic potential of liposomal formulations involves the 
use of so-called lipopeptides. These structures consist of lipids linked to peptides that 
contain potential CD4+ and CD8+ T cell epitopes. These vaccines aim at the induction of 
strong T cell responses in HIV-1 infected patients [237-239]. Currently, a lipopeptide-pulsed 
DC vaccine is under evaluation in a phase I/II clinical trial in HAART-treated patients 
chronically infected with HIV-1 [240]. 
6.3.2 Cationic lipid based lipoplexes 
The combination of positively charged lipids and negatively charged nucleic acids results in 
spontaneous formation of complexes called lipoplexes (figure 7c). These systems typically 
consist of two lipid species: a cationic lipid (such as DOTAP - 1,2-dioleoyl-3-
trimethylammonium-propane) and a helper lipid with long unsaturated fatty acid chains 
(such as DOPE - dioleoylphosphatidylethanolamine) (figure 7). New cationic lipids are 
being synthesized almost daily aiming at introducing additional positive charges and 
reducing toxicity. Helper lipids are introduced to facilitate endosomal escape of these 
complexes [241]. 
The positive charge of lipoplexes promotes their cellular uptake, which was found to occur 
via clathrin-dependent and independent endocytosis [243-245]. The route of lipoplex uptake 
is determined by their size, chemical nature of the lipids and the cell line. After being 
internalised, the lipoplexes are located in endosomes. Escape from these compartments 
probably occurs via a mechanism proposed by Xu and Szoka [246]. It implies formation of 
neutral molecular pairs of lipoplex-derived cationic lipids and negatively charged 
phospholipids present in the endosomal membrane, eventually leading to release of the 
nucleic acid into the cytoplasm. 
 
Figure 7. Chemical structures of DOTAP, cationic lipid, and DOPE, neutral helper lipid, used to form 
lipoplexes [213, 242]. DOTAP (a) and DOPE (b) contain a hydrophilic head group, a glycerol linker 
and two hydrophobic fatty acid chains. (c) Schematic representation of a lipoplex containing nucleic 
acids (blue) stabilized by bilayer of lipids: hydrophilic groups (red), hydrophobic fatty acid chain 
(grey). 
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Lipoplexes are mainly used to transfect primary cells or cell lines in vitro. However, since the 
rise of DNA vaccines, cationic lipids are considered as a versatile method to replace the 
hazardous viral vectors. In mice DNA lipoplexes have been shown to induce antitumor 
activity [247] and both antibody and Th1 cellular responses against hepatitis C virus [248, 
249]. In the late eighties the first transfection with mRNA-lipoplexes was performed [250]. 
Generally it is established that mRNA transfection using non-viral cationic carriers is more 
efficient with cationic lipids than with cationic polymers [191, 192, 251, 252]. For both types 
of mRNA complexes the onset of protein expression was faster, but also lasted shorter than 
that produced by pDNA-complexes [191, 252]. The potential of mRNA-lipoplexes as an anti-
cancer or influenza vaccine dates back to the nineties [253, 254]. Since then most anti-cancer 
and anti-virus immunotherapies have been focused on the ex vivo loading of DCs mainly by 
means of electroporation [109, 196, 198, 255, 256]. 
One of the most serious challenges of the use of lipoplexes is the extrapolation from the in 
vitro to the in vivo situation. Optimal transfection conditions are maintained in vitro, while in 
vivo lipoplexes encounter serum proteins causing their aggregation [257]. Depending on the 
target cells or tissue, this aggregation can either negatively or positively affect the uptake of 
the lipoplexes [258, 259]. Additional coating of the lipoplexes with polyethyleneglycol (PEG) 
can prevent the formation of aggregates [260], yet brings along other problems. Concerns 
have been raised that PEGylation of lipoplexes may be unfavorable in the context of 
vaccination as this could inhibit uptake of nanoparticles by APCs and negatively interfere 
with the release of complexes from the endosomal compartment [213]. However, a study 
performed by Singh and colleagues demonstrated that subcutaneous immunization of 
rabbits with PEGylated lipoplexes carrying a synthetic gp41 epitope of HIV-1 induced two 
times higher immune responses and prolonged persistence of antibodies than liposomes 
carrying epitopes without PEG moieties [261].  
6.4. Targeting of DCs 
Conceptually, particulate vaccines mimic the particulate nature of pathogens, including the 
size (nano- to micro-meter range), which facilitates their uptake by APCs. The actual size of 
the particles influences the uptake mechanism by APCs and the way of antigen 
presentation. Generally, larger particles are predominantly internalised via phagocytosis or 
macropinocytosis, while smaller particles are taken up by other endocytic mechanisms [262-
264]. Internalisation through phagocytosis is known to lead to antigen cross-presentation in 
DCs [265, 266]. This emphasizes the enhanced potential of particulate antigen delivery to 
induce cellular immune responses as compared to soluble antigens, which are poorly cross-
presented and preferentially presented via the MHC class II pathway. 
Most nano- or microparticles can be functionalized with ligands or antibodies directed 
against cell surface receptors to target specific tissues or cells [267]. DCs express lectin-like 
receptors such as mannose receptor, DEC-205 and DC-SIGN which are believed to be 
involved in the phagocytosis of pathogens [268]. One way of increasing or promoting 
particle uptake by DCs is the attachment of mannose groups recognized by the mannose 
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receptors present on DCs and macrophages. This has been shown to increase transfection 
efficiency of DNA-based vaccines [269, 270], antigen presentation following protein delivery 
[271] and the induction of cellular T cell responses in cancer and HIV immunotherapeutic 
strategies using lipoplexes and polyplexes [228, 270]. Another way of targeting is the use of 
ligands or antibodies directed against DEC-205 or DC-SIGN, which have shown potential to 
improve antigen uptake by immature and mature DCs [272-275]. It should be kept in mind, 
however, that attaching the desired ligand or protein is not always a straightforward 
process. The engraftment of chelator lipids on the surface of liposomes or lipoplexes, such as 
histidine tags, is crucial to ensure the functionality of the coupled target molecule [276-278]. 
In this context, the use of nanobodies directed against DCs could be of particular interest as 
they are mostly generated with a histidine tag for purification purposes. Alternatively, 
ligands could also be linked to liposomes via palmitoylation of the ligand [279]. 
In summary, targeting of particles may not only enhance efficacy but also the specificity of 
interaction with the surface receptors on DCs [179]. Moreover, coupling of specific adjuvants 
(e.g. TLR ligands), with the aim to promote the desired immune response, can also 
positively influence the uptake by DCs [280]. 
6.5. Co-delivery of antigens and adjuvants to improve immunogenicity of DCs 
Although particulate antigen delivery improves antigen uptake and presentation by DCs, 
most particles are not immunogenic by themselves. This offers a possibility to use a specific 
adjuvant that can skew towards the desired type of immune responses [187]. Despite some 
positive results in animal models, one should be aware of the toxicity of potential 
immunomodulators in humans, that jeopardizes their clinical use [281]. Aluminum salts 
(referred to as alum) are the oldest and most widely used adjuvants for human vaccines. It 
has been shown that antigens can be precipitated with alum to form colloid particles, 
creating a depot effect after vaccination, that elicits strong humoral immune responses [282]. 
These results, together with further observations clearly showed that the physical linkage of 
antigen and immunomodulator is crucial to induce strong immune responses [182, 183, 283]. 
Immunostimulating complexes (ISCOMs) are another interesting delievery system. It is a 
sort of liposomal delivery vehicle with a built-in adjuvant. They are composed of a protein 
antigen, phosopholipids and the saponin Quil A adjuvant, derived from the bark of the 
Quillaja saponaria, a South American tree. It has been demonstrated that the use of ISCOMs 
improves CTL responses of influenza virus based vaccines [284, 285]. ISCOM-based vaccines 
have been tested in animal models and in clinical trials against cancer [286] and viral 
infections [287-289] [290, 291]. In all studies satisfactory safety and tolerance were shown 
and both humoral and cellular responses were induced.  
Several studies have reported the use of ISCOMs as a system to deliver HIV or SIV antigens. 
In non-human primate models, incorporation of HIV or SIV peptides into ISCOMs has been 
shown to induce protective immunity [288, 292, 293]. Moreover, studies in mice 
demonstrated that ISCOMs can be used to elicit immune responses against HIV-1 antigens 
[287]. To generate mucosal immunity, Koopman and colleagues immunized rhesus 
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maquaqes intranasally or via lymph nodes with HIV-1 peptides formulated into PR8-Flu 
ISCOMs [294]. Intranodal injection of these ISCOMs induced strong systemic and mucosal 
immune responses. In contrast, intranasal application resulted in very weak responses. 
Currently, ISCOM-based vaccines have been approved for veterinary use and are 
undergoing clinical trials for human use [295]. 
As described before, for an optimal immune response it is crucial that DCs, besides actively 
taking up the antigen, undergo activation and maturation to stimulate effective T cell 
responses. Ligands mimicking PAMPs that can target PPRs are therefore of potential 
interest. Extracellular and intracellular PPRs are divided into four groups: TLRs, NLRs, 
CLRs and RLRs [181]. Depending on the receptor that is triggered, DCs produce and secrete 
various sets of cytokines, determining the type of immune response [296]. Moreover, the 
incorporation of TLR ligands promotes phagocytosis of APCs [280]. TLRs represent the 
majority of PPRs studied in the development of effective adjuvants [281]. TLRs can be 
divided into two groups: the surface bound receptors (TLR 1, 2, 4, 5, 6) and the intracellular 
receptors present in the endosomes (TLR 3, 7, 8, 9) (table 4). 
 
TLR TLR ligand DC subset Effect of activation
1:2 Triacyl lipoproteins Mo-DCs, 
myeloid DCs 
Upregulation of CCR7, IL-6, IL-10, IL-
12p70,TNF-α 
2 Lipoproteins Mo-DCs, 
myeloid DCs 
Upregulation of CCR7, IL-6, IL-10, IL-
12p70,TNF-α 
3 Double stranded 
RNA 
Mo-DCs, 
myeloid DCs 
IFN-α/β activation and up-regulation IL-
12p70 
4 Lipopolysaccharide Mo-DCs, 
myeloid DCs 
Upregulation of CD80, CD86, CD83, CCR7.  
Secretion of  IL-6, IL-8, IL-10, IL-12p70, IFN-
β
5 Flagellin Mo-DCs, 
myeloid DCs 
Upregulation of CD80, CD86, CD83, CCR7.  
Secretion IFN-α/β , IL-1 , TNF-α, IL-8, IL-
12p40 
6:2 Triacyl lipoproteins Mo-DCs, 
myeloid DCs 
Upregulation of CCR7, IL-6, IL-10, IL-
12p70,TNF-α 
7 Single stranded 
mRNA 
pDC, myeloid 
DCs 
Upregulation of CCR7,CD40, CD80 and 
CD86. Secretion of IL-12p70 (myeloid DCs). 
Secretion of IFN-α (pDCs). 
8 Single stranded 
mRNA 
Mo-DCs Increased TNF , IL-8, IL-12p40, MCP-1, 
CCL2, CCL3, CCL4, CCL5 
9 Double stranded 
DNA 
pDC Upregulation of CD40, CD80, CD86, CD83, 
HLA-DR, CCR7. Upregulation of IFN-α 
(very high), IFN-β (lower), IL-6, TNF-α  
(low), IL-8
Table 4. Overview of Toll like receptors (TLRs) with their ligands and effect of activation [297]. 
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The extracellular TLRs mainly recognize bacterial invaders, but also fungi and some 
enveloped viruses. Bacterial lipoproteins are recognized by the heterodimers TLR1:2 (triacyl 
lipoproteins) and TLR2:6 (diacyl lipoproteins). Liposomes engrafted with palmitoyl chain 
lipopeptides have been shown to up-regulate DC maturation markers in vitro [298]. 
Lipopolysaccharide (LPS), a gram negative bacterial carbohydrate, is recognized by TLR4. 
Recently, a phase I clinical trial has started evaluating the potential of autologous dendritic 
cells, ex vivo loaded with lipopeptides and activated with LPS, as an immunotherapy in HIV 
infected patients (NCT00796770). Lipopolysaccharide (LPS), a gram negative bacterial 
carbohydrate, is recognized by TLR4. Since the in vivo use of LPS for human purposes is not 
possible due to the risk of septic shocks, a derivative, monophosphoryl lipid A from 
Salmonella Minnesota referred to as MPLA, was proposed as a substitute. It has been shown 
to be less toxic than LPS and thus preferable for human vaccine applications. MPLA has 
been incorporated in PLGA particles and liposomes [299, 300]. Furthermore, MPLA is 
already used in combination with alum (AS04) as an adjuvant in Cervarix®, a human 
papilloma virus vaccine from GlaxoSmithKline. Another bacterial component, flagellin, is 
recognized by TLR5 and is also used as a potential adjuvant. Flagellin-related peptides 
containing a His-tag and incorporated in liposomes containing a tumor antigen, induced 
antitumor responses resulting in complete tumor regression in mice [278]. The advantage of 
flagellin is that it can be co-integrated as a protein into particulate vehicles or integrated as 
His-tagged peptides into liposomes. 
The intracellular TLRs specifically recognize nucleic acids and are of major importance to 
the recognition of double stranded DNA (dsDNA) from viral or bacterial intruders. TLR-9, 
only expressed in pDCs, recognizes unmethylated cytosine-phosphate-guanine (CpG) 
oligodeoxynucleotides (ODNs). CpG motifs were demonstrated to induce cell-mediated 
responses in vivo when incorporated into PLGA particles [301, 302], liposomes [303] and 
other microparticles [304]. All these studies reported enhanced Th1 biased immune 
responses. Viral single stranded RNA (ssRNA) is recognized by TLR7 (expressed by all DC 
subsets and B-cells) and TLR8 (expressed by macrophages, monocytes and myeloid DCs) 
[181]. Agonists used to trigger these receptors are the synthetic imidazoquinoline drug 
compounds imiquimod and resiquimod (R848) or polyuridylic acid (polyU). Only few 
studies so far have used TLR7/8 ligands for particulate antigen delivery. Johnston et al. 
demonstrated that the combination of TLR 7 ligand with liposomes increased the cellular 
immune responses against OVA protein in a mice model [305]. Another study reported that 
co-encapsulation of OVA antigen and polyU in PLA-DOTAP microparticles increased the 
antibody titers and numbers of IFN-γ secreting T cells [306]. Finally, the endosomal TLR3 
recognizes dsRNA, which can be mimicked by the synthetic polyinosinic:polycytidylic acid 
(poly I:C). This dsRNA analog is widely evaluated as a potential adjuvant since it strongly 
promotes the maturation of DCs [184, 204]. Furthermore, the combination of poly I:C with 
protein antigens encapsulated in either polymeric [183, 184, 307] or liposomal [308] particles 
favors enhanced Th1 immune responses. With regard to mRNA vaccination, the use of 
endosomal TLR ligands is problematic, since upon recognition by their receptor, high levels 
of type I interferon are produced leading to the activation of RNases [309, 310]. However, 
mRNA by itself can also trigger endosomal TLRs, implying the crucial importance of 
stabilizing the antigen encoding mRNA (reviewed by Tavernier et al.) [189]. 
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Another possibility to improve immunogenicity is the addition of co-stimulatory molecules. 
The addition of CD40L to DCs loaded with liposome-complexed HIV-1 proteins could 
prime HIV-1 specific CD8+ T cells in vitro [162]. Within the scope of mRNA transfection, 
mRNA encoding co-stimulatory molecules can be co-transfected with mRNA encoding an 
antigen, which has been shown to strongly enhance the capacity of electroporated DCs to 
stimulate HIV-specific T cell responses [311].  
7. Concluding remarks 
Ex vivo loading of DCs shows promising results as an immunotherapy for HIV and cancer. 
However, the currently applied strategy is not applicable on a large scale, especially in 
Africa where the largest incidence of HIV infections is observed. The use of particulate 
vehicles able to directly deliver the antigen of interest, be it proteins, peptides or nucleic 
acids,  into DCs in vivo is a very attractive concept. Different antigen formulations can be 
further tailored with targeting antibodies or immunomodulatory ligands to promote uptake 
by DCs and to trigger the desired type of immune response. In the context of HIV 
immunotherapy a large number of epitopes needs to cover a broad panel of quasi species. 
Therefore, mRNA-based vaccination strategies present an attractive option. In contrast to 
pDNA, mRNA needs to be delivered only into the cytoplasm and induces transient antigen 
expression without the risk of genomic insertion. Further research will be required for 
designing an optimal carrier system preferably comprising an adjuvant, necessary to 
achieve strong HIV-specific CTL responses with the ultimate goal to control viral replication 
in the absence of additional HAART therapy. 
Author details 
Winni De Haes 
Institute of Tropical Medicine of Antwerp, Department of Biomedical Sciences, Virology Unit, 
Antwerp, Belgium 
Charlotte Pollard 
Institute of Tropical Medicine of Antwerp, Department of Biomedical Sciences, Virology Unit, 
Antwerp, Belgium 
Laboratory of Molecular Immunology, Ghent University, Belgium 
Guido Vanham 
Institute of Tropical Medicine of Antwerp, Department of Biomedical Sciences, Virology Unit, 
Antwerp, Belgium 
Faculty of Pharmaceutical, Veterinary and Biomedical Sciences, University of Antwerp, Belgium 
Faculty of Medicine and Pharmacology, Vrije Universiteit Brussel, Belgium 
Joanna Rejman 
Laboratory of General Biochemistry and Physical Pharmacy, Ghent University, Belgium 
 
“Wrapped Up” Vaccines in the Context of HIV-1 Immunotherapy 55 
Acknowledgement 
This work was supported by grants from IUAP (Inter-University Attraction Poles, P6/41 of 
the Belgian government), FWO (Fund for Scientific Research Flanders, project number 
G.0226.10) and SOFI-B (Secondary Research Funding ITM). W. De Haes is a doctoral fellow 
of the Institute for Science and Technology (IWT), Flanders. There is no conflict of interest. 
8. References 
[1] Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. 
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune 
deficiency syndrome (AIDS). Science. 1983;220(4599):868-71. 
[2] Gallo RC, Sarin PS, Gelmann EP, Robert-Guroff M, Richardson E, Kalyanaraman VS, et 
al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome 
(AIDS). Science. 1983;220(4599):865-7. 
[3] UNAIDS. UNAIDS Global report 2010. wwwunaidsorg. 2010. 
[4] Coffin J, Haase A, Levy JA, Montagnier L, Oroszlan S, Teich N, et al. Human 
immunodeficiency viruses. Science. 1986;232(4751):697. 
[5] Haseltine WA. Molecular biology of the human immunodeficiency virus type 1. FASEB 
J. 1991;5(10):2349-60. 
[6] Gotte M, Li X, Wainberg MA. HIV-1 reverse transcription: a brief overview focused on 
structure-function relationships among molecules involved in initiation of the reaction. 
Arch Biochem Biophys. 1999;365(2):199-210. 
[7] Farnet CM, Haseltine WA. Determination of viral proteins present in the human 
immunodeficiency virus type 1 preintegration complex. J Virol. 1991;65(4):1910-5. 
[8] Sierra S, Kupfer B, Kaiser R. Basics of the virology of HIV-1 and its replication. J Clin 
Virol. 2005;34(4):233-44. 
[9] Jaffe HW, Bregman DJ, Selik RM. Acquired immune deficiency syndrome in the United 
States: the first 1,000 cases. J Infect Dis. 1983;148(2):339-45. 
[10] Levy JA. HIV pathogenesis: 25 years of progress and persistent challenges. AIDS. 
2009;23(2):147-60. 
[11] Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A, et al. Severe CD4+ 
T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus 
type 1 infection and substantial delay in restoration following highly active 
antiretroviral therapy. J Virol. 2003;77(21):11708-17. 
[12] Cowley S. The biology of HIV infection. Lepr Rev. 2001;72(2):212-20. 
[13] Pantaleo G, Fauci AS. Immunopathogenesis of HIV infection. Annu Rev Microbiol. 
1996;50:825-54. 
[14] Buchbinder S, Vittinghoff E. HIV-infected long-term nonprogressors: epidemiology, 
mechanisms of delayed progression, and clinical and research implications. Microbes 
Infect. 1999;1(13):1113-20. 
 Immunodeficiency 56 
[15] Saez-Cirion A, Pancino G, Sinet M, Venet A, Lambotte O. HIV controllers: how do they 
tame the virus? Trends Immunol. 2007;28(12):532-40. 
[16] Shearer G, Clerici M. Historical perspective on HIV-exposed seronegative individuals: 
has nature done the experiment for us? J Infect Dis. 2010;202 (Suppl 3):329-32. 
[17] Palella FJ, Delaney K, Moorman A, Loveless M, Fuhrer J, Satten G, et al. Declining 
morbidity and mortality among patients with advanced human immunodeficiency 
virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853-60. 
[18] Pomerantz RJ, Horn DL. Twenty years of therapy for HIV-1 infection. Nat Med. 2003 
Jul;9(7):867-73. 
[19] Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte AdA, El-Sadr W, et al. Class of 
antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 
2007;356(17):1723-35. 
[20] Hawkins T. Understanding and managing the adverse effects of antiretroviral therapy. 
Antiviral Res. 2010 Jan;85(1):201-9. 
[21] Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, 
prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, 
hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353(9170):2093-9. 
[22] Autran B, Carcelaint G, Li TS, Gorochov G, Blanc C, Renaud M, et al. Restoration of the 
immune system with anti-retroviral therapy. Immunol Lett. 1999;66(1-3):207-11. 
[23] Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 
expression on HIV-specific T cells is associated with T-cell exhaustion and disease 
progression. Nature. 2006;443(7109):350-4. 
[24] Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated CD38 
antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV 
disease progression to AIDS and death in the Multicenter AIDS Cohort Study than 
CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and 
CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16(2):83-92. 
[25] Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial 
translocation is a cause of systemic immune activation in chronic HIV infection. Nat 
Med. 2006;12(12):1365-71. 
[26] Mandl JN, Barry AP, Vanderford TH, Kozyr N, Chavan R, Klucking S, et al. Divergent 
TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and 
nonpathogenic AIDS virus infections. Nat Med. 2008;14(10):1077-87. 
[27] Harris LD, Tabb B, Sodora DL, Paiardini M, Klatt NR, Douek DC, et al. Downregulation 
of robust acute type I interferon responses distinguishes nonpathogenic simian 
immunodeficiency virus (SIV) infection of natural hosts from pathogenic SIV infection 
of rhesus macaques. J Virol. 2010;84(15):7886-91. 
[28] Silvestri G, Sodora DL, Koup RA, Paiardini M, O'Neil SP, McClure HM, et al. 
Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander 
immunopathology despite chronic high-level viremia. Immunity. 2003;18(3):441-52. 
 
“Wrapped Up” Vaccines in the Context of HIV-1 Immunotherapy 57 
[29] Sempere JM, Soriano V, Benito JM. T regulatory cells and HIV infection. AIDS Rev. 
2007;9(1):54-60. 
[30] Epple H-J, Loddenkemper C, Kunkel D, Troger H, Maul J, Moos V, et al. Mucosal but 
not peripheral FOXP3+ regulatory T cells are highly increased in untreated HIV 
infection and normalize after suppressive HAART. Blood. 2006;108(9):3072-8. 
[31] Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol. 2002;2(9):706-13. 
[32] Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and 
escape by HIV-1. Nature. 2003;422(6929):307-12. 
[33] Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated 
during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med. 
2009;15(8):866-70. 
[34] Aasa-Chapman MMI, Holuigue S, Aubin K, Wong M, Jones NA, Cornforth D, et al. 
Detection of antibody-dependent complement-mediated inactivation of both 
autologous and heterologous virus in primary human immunodeficiency virus type 1 
infection. J Virol. 2005;79(5):2823-30. 
[35] Hessell AJ, Hangartner L, Hunter M, Havenith CEG, Beurskens FJ, Bakker JM, et al. Fc 
receptor but not complement binding is important in antibody protection against HIV. 
Nature. 2007;449(7158):101-4. 
[36] McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. Nature. 
2001;410(6831):980-7. 
[37] Gehri R, Hahn S, Rothen M, Steuerwald M, Nuesch R, Erb P. The Fas receptor in HIV 
infection: expression on peripheral blood lymphocytes and role in the depletion of T 
cells. AIDS. 1996;10(1):9-16. 
[38] Saksena NK, Wu JQ, Potter SJ, Wilkinson J, Wang B. Human immunodeficiency virus 
interactions with CD8+ T lymphocytes. Curr HIV Res. 2008;6(1):1-9. 
[39] Bernardin F, Kong D, Peddada L, Baxter-Lowe LA, Delwart E. Human 
immunodeficiency virus mutations during the first month of infection are preferentially 
found in known cytotoxic T-lymphocyte epitopes. J Virol. 2005;79(17):11523-8. 
[40] Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. HIV-1 Nef protein protects 
infected primary cells against killing by cytotoxic T lymphocytes. Nature. 
1998;391(6665):397-401. 
[41] Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, et al. 
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. 
Science. 1997;278(5342):1447-50. 
[42] Lichterfeld M, Kaufmann DE, Yu XG, Mui SK, Addo MM, Johnston MN, et al. Loss of 
HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by 
vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med. 2004;200(6):701-12. 
[43] Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, et al. Dramatic rise in 
plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected 
macaques. J Exp Med. 1999;189(6):991-8. 
 Immunodeficiency 58 
[44] Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, et al. Control of 
viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 
1999;283(5403):857-60. 
[45] Feeney ME, Tang Y, Roosevelt K, Leslie A, McIntosh K, Karthas N, et al. Immune 
escape precedes breakthrough human immunodeficiency virus type 1 viremia and 
broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-term-
nonprogressing child. J Virol. 2004;78(16):8927-30. 
[46] Kemal KS, Beattie T, Dong T, Weiser B, Kaul R, Kuiken C, et al. Transition from long-
term nonprogression to HIV-1 disease associated with escape from cellular immune 
control. J Acquir Immune Defic Syndr. 2008;48(2):119-26. 
[47] Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al. Resistance to 
HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine 
receptor gene. Nature. 1996;382(6593):722-5. 
[48] Hutter G, Ganepola S. Eradication of HIV by transplantation of CCR5-deficient 
hematopoietic stem cells. ScientificWorldJournal. 2011;11:1068-76. 
[49] Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, et al. Long-term 
control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 
2009;360(7):692-8. 
[50] Chiu Y-L, Greene WC. Multifaceted antiviral actions of APOBEC3 cytidine deaminases. 
Trends Immunol. 2006;27(6):291-7. 
[51] Croxford JL, Gasser S. Damage control: how HIV survives the editor APOBEC3G. Nat 
Immunol. 2011;12(10):925-7. 
[52] Ulenga NK, Sarr AD, Thakore-Meloni S, Sankale J-L, Eisen G, Kanki PJ. Relationship 
between human immunodeficiency type 1 infection and expression of human 
APOBEC3G and APOBEC3F. J Infect Dis. 2008;198(4):486-92. 
[53] Johnson WE, Sawyer SL. Molecular evolution of the antiretroviral TRIM5 gene. 
Immunogenetics. 2009;61(3):163-76. 
[54] Neil SJD, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized 
by HIV-1 Vpu. Nature. 2008;451(7177):425-30. 
[55] Bailey JR, Williams TM, Siliciano RF, Blankson JN. Maintenance of viral suppression in 
HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med. 
2006;203(5):1357-69. 
[56] Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S, et al. 
Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. 
Nature. 2004;432(7018):769-75. 
[57] Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, et 
al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of 
HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A. 2000;97(6):2709-14. 
[58] Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, et al. Innate partnership of 
HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet. 2007;39(6):733-40. 
 
“Wrapped Up” Vaccines in the Context of HIV-1 Immunotherapy 59 
[59] Qi Y, Martin MP, Gao X, Jacobson L, Goedert JJ, Buchbinder S, et al. KIR/HLA 
pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog. 
2006;2(8):79. 
[60] Devito C, Broliden K, Kaul R, Svensson L, Johansen K, Kiama P, et al. Mucosal and 
plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis 
across human epithelial cells. J Immunol. 2000;165(9):5170-6. 
[61] Kaul R, Trabattoni D, Bwayo JJ, Arienti D, Zagliani A, Mwangi FM, et al. HIV-1-specific 
mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS. 1999;13(1):23-9. 
[62] Mazzoli S, Trabattoni D, Lo Caputo S, Piconi S, Ble C, Meacci F, et al. HIV-specific 
mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive 
individuals. Nat Med. 1997;3(11):1250-7. 
[63] Gupta P, Balachandran R, Ho M, Enrico A, Rinaldo C. Cell-to-cell transmission of 
human immunodeficiency virus type 1 in the presence of azidothymidine and 
neutralizing antibody. J Virol. 1989;63(5):2361-5. 
[64] El-Far M, Halwani R, Said E, Trautmann L, Doroudchi M, Janbazian L, et al. T-cell 
exhaustion in HIV infection. Curr HIV/AIDS Rep. 2008;5(1):13-9. 
[65] Almeida JR, Sauce D, Price DA, Papagno L, Shin SY, Moris A, et al. Antigen sensitivity 
is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. 
Blood. 2009;113(25):6351-60. 
[66] Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, Bornstein E, et al. Superior 
control of HIV-1 replication by CD8+ T cells is reflected by their avidity, 
polyfunctionality, and clonal turnover. J Exp Med. 2007;204(10):2473-85. 
[67] Derby M, Alexander-Miller M, Tse R, Berzofsky J. High-avidity CTL exploit two 
complementary mechanisms to provide better protection against viral infection than 
low-avidity CTL. J Immunol. 2001;166(3):1690-7. 
[68] Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart P-A, Pantaleo G. HIV-1-specific 
IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-
1-specific CD8 T cells. PNAS. 2005;102(20):7239-44. 
[69] Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV 
nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. 
Blood. 2006 Jun 15;107(12):4781-9. 
[70] Geldmacher C, Currier JR, Herrmann E, Haule A, Kuta E, McCutchan F, et al. CD8 T-
cell recognition of multiple epitopes within specific Gag regions is associated with 
maintenance of a low steady-state viremia in human immunodeficiency virus type 1-
seropositive patients. J Virol. 2007;81(5):2440-8. 
[71] Martinez-Picado J, Prado JG, Fry EE, Pfafferott K, Leslie A, Chetty S, et al. Fitness cost of 
escape mutations in p24 Gag in association with control of human immunodeficiency 
virus type 1. J Virol. 2006;80(7):3617-23. 
[72] Sanchez-Merino V, Farrow MA, Brewster F, Somasundaran M, Luzuriaga K. 
Identification and characterization of HIV-1 CD8+ T cell escape variants with impaired 
fitness. J Infect Dis. 2008;197(2):300-8. 
 Immunodeficiency 60 
[73] Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, Le Gall S, et al. Escape from 
the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated 
with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol. 
2007;81(22):12382-93. 
[74] Harari A, Petitpierre S, Vallelian F, Pantaleo G. Skewed representation of functionally 
distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with 
progressive disease: changes after antiretroviral therapy. Blood. 2004;103(3):966-72. 
[75] Makedonas G, Betts MR. Living in a house of cards: re-evaluating CD8 T-cell immune 
correlates against HIV. Immunol Rev. 2011;239(1):109-24. 
[76] Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, Hooker DJ, et al. 
Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion 
donor and recipients. Science. 1995;270(5238):988-91. 
[77] Walker BD, Burton DR. Toward an AIDS vaccine. Science. 2008;320:760-4. 
[78] Wijesundara DK, Jackson RJ, Ramshaw IA, Ranasinghe C. Human immunodeficiency 
virus-1 vaccine design: where do we go now? Immunol Cell Biol. 2011;89:367-74. 
[79] Hirbod T, Broliden K. Mucosal immune responses in the genital tract of HIV-1-exposed 
uninfected women. J Intern Med. 2007;262:44-58. 
[80] Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, et al. 
Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against 
mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 
2009;5(5):e1000433. 
[81] Ruprecht RM, Hofmann-Lehmann R, Smith-Franklin BA, Rasmussen RA, Liska V, 
Vlasak J, et al. Protection of neonatal macaques against experimental SHIV infection by 
human neutralizing monoclonal antibodies. Transfus Clin Biol. 2001;8:350-8. 
[82] Reynolds MR, Weiler AM, Weisgrau KL, Piaskowski SM, Furlott JR, Weinfurter JT, et 
al. Macaques vaccinated with live-attenuated SIV control replication of heterologous 
virus. J Exp Med. 2008;205:2537-50. 
[83] Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, et al. HIV 
vaccine design and the neutralizing antibody problem. Nat Immunol. 2004;5:233-6. 
[84] Roux KH, Taylor KA. AIDS virus envelope spike structure. Curr Opin Struct Biol. 
2007;17:244-52. 
[85] Derby NR, Kraft Z, Kan E, Crooks E, Barnett S, Srivastava I, et al. Antibody responses 
elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) 
SF162-derived gp140 envelope immunogens: comparison with those elicited during 
homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous 
HIV-1 infection. J Virol. 2006;80(17):8745-62. 
[86] Wilson NA, Reed J, Napoe G, Piaskowski S, Szymanski A, Furlott J, et al. Vaccine-
induced cellular immune responses reduce plasma viral concentrations after repeated 
low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J 
Virol. 2006;80(12):5875-85. 
 
“Wrapped Up” Vaccines in the Context of HIV-1 Immunotherapy 61 
[87] Genescà M. Characterization of an effective CTL response against HIV and SIV 
infections. J Biomed Biotechnol. 2011;2011:103924. 
[88] Cheynier R, Langlade-Demoyen P, Marescot MR, Blanche S, Blondin G, Wain-Hobson 
S, et al. Cytotoxic T lymphocyte responses in the peripheral blood of children born to 
human immunodeficiency virus-1-infected mothers. Eur J Immunol. 1992;22:2211-7. 
[89] Schenal M, Lo Caputo S, Fasano F, Vichi F, Saresella M, Pierotti P, et al. Distinct 
patterns of HIV-specific memory T lymphocytes in HIV-exposed uninfected individuals 
and in HIV-infected patients. AIDS. 2005;19:653-61. 
[90] Jennes W, Vuylsteke B, Borget M-Y, Traore-Ettiegne V, Maurice C, Nolan M, et al. HIV-
specific T helper responses and frequency of exposure among HIV-exposed 
seronegative female sex workers in Abidjan, Cote d'Ivoire. J Infect Dis. 2004;189:602-10. 
[91] Kaul R, Dong T, Plummer FA, Kimani J, Rostron T, Kiama P, et al. CD8(+) lymphocytes 
respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest. 
2001;107:1303-10. 
[92] McElrath MJ, Haynes BF. Induction of immunity to human immunodeficiency virus 
type-1 by vaccination. Immunity. 2010;33:542-54. 
[93] Goepfert PA, Tomaras GD, Horton H, Montefiori D, Ferrari G, Deers M, et al. Durable 
HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein 
recombinant vaccine in uninfected human volunteers. Vaccine. 2007;25:510-18. 
[94] Jones NG, DeCamp A, Gilbert P, Peterson ML, Gurwith M, Cao H. AIDSVAX 
immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative 
volunteers who subsequently acquire HIV infection. Vaccine. 2009;27:1136-40. 
[95] Taneichi M, Tanaka Y, Kakiuchi T, Uchida T. Liposome-coupled peptides induce long-
lived memory CD8 T cells without CD4 T cells. PLoS One. 2010;5(11):e15091. 
[96] Doan LX, Li M, Chen C, Yao Q. Virus-like particles as HIV-1 vaccines. Rev Med Virol. 
2005;15:75-88. 
[97] Papagno L, Alter G, Assoumou L, Murphy RL, Garcia F, Clotet B, et al. Comprehensive 
analysis of virus-specific T-cells provides clues for the failure of therapeutic 
immunization with ALVAC-HIV vaccine. Aids. 2011 Jan 2;25(1):27-36. 
[98] Sandstrom E, Nilsson C, Hejdeman B, Brave A, Bratt G, Robb M, et al. Broad 
immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with 
heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis. 
2008;198:1482-90. 
[99] Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, Schmidt C, et al. Studies of a 
prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) 
with and without DNA priming: effects of dosage and route on safety and 
immunogenicity. Vaccine. 2007;25:2120-7. 
[100] Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, et al. Cross-subtype 
antibody and cellular immune responses induced by a polyvalent DNA prime-protein 
boost HIV-1 vaccine in healthy human volunteers. Vaccine. 2008;26:1098-110. 
 Immunodeficiency 62 
[101] Connolly NC, Whiteside TL, Wilson C, Kondragunta V, Rinaldo CR, Riddler SA. 
Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) 
peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected 
individuals. Clin Vaccine Immunol. 2008 Feb;15(2):284-92. 
[102] Gandhi RT, O'Neill D, Bosch RJ, Chan ES, Bucy RP, Shopis J, et al. A randomized 
therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV 
alone in HIV-1-infected patients on antiretroviral therapy. Vaccine. 2009;27:6088-94. 
[103] Garcia F, Climent N, Assoumou L, Gil C, Gonzalez N, Alcami J, et al. A therapeutic 
dendritic cell-based vaccine for HIV-1 infection. J Infect Dis. 2011;203:473-8. 
[104] Garcia F, Lejeune M, Climent N, Gil C, Alcami J, Morente V, et al. Therapeutic 
immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in 
patients with chronic HIV-1 infection. J Infect Dis. 2005 May 15;191(10):1680-5. 
[105] Ide F, Nakamura T, Tomizawa M, Kawana-Tachikawa A, Odawara T, Hosoya N, et al. 
Peptide-loaded dendritic-cell vaccination followed by treatment interruption for 
chronic HIV-1 infection: a phase 1 trial. J Med Virol. 2006 Jun;78(6):711-8. 
[106] Kloverpris H, Karlsson I, Bonde J, Thorn M, Vinner L, Pedersen AE, et al. Induction of 
novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization 
with subdominant cytotoxic T-lymphocyte epitopes. AIDS. 2009;23:1329-40. 
[107] Kundu SK, Engleman E, Benike C, Shapero MH, Dupuis M, van Schooten WC, et al. A 
pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell 
therapy in HIV-infected patients. AIDS Res Hum Retroviruses. 1998 May 1;14(7):551-60. 
[108] Lu W, Arraes LC, Ferreira WT, Andrieu J-M. Therapeutic dendritic-cell vaccine for 
chronic HIV-1 infection. Nat Med. 2004;10:1359-65. 
[109] Routy J-P, Boulassel M-R, Yassine-Diab B, Nicolette C, Healey D, Jain R, et al. 
Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells 
in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol. 2010;134:140-
7. 
[110] Poon B, Safrit J, McClure H, Kitchen C, Hsu J, Gudeman V, et al. Induction of humoral 
immune responses following vaccination with envelope-containing, formaldehyde-
treated, thermally inactivated human immunodeficiency virus type 1. J Virol. 
2005;79(8):4927-35. 
[111] Girard MP, Osmanov S, Kieny M. A review of vaccine research and development: the 
human immunodeficiency virus (HIV). Vaccine. 2006;24(19):4062-81. 
[112] Girard MP, Osmanov S, Assossou OM, Kieny M-P. Human immunodeficiency virus 
(HIV) immunopathogenesis and vaccine development: a review. Vaccine. 2011;29:6191-
218. 
[113] Polo JM, Dubensky TW. Virus-based vectors for human vaccine applications. Drug 
Discov Today. 2002;7:719-27. 
[114] Liu MA. Immunologic basis of vaccine vectors. Immunity. 2010;33:504-15. 
 
“Wrapped Up” Vaccines in the Context of HIV-1 Immunotherapy 63 
[115] Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy 
assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, 
randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372:1881-93. 
[116] McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al. HIV-1 
vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. 
Lancet. 2008;372:1894-905. 
[117] Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for 
future vaccine development? J Exp Med. 2008 Jan 21;205(1):7-12. 
[118] Abbink P, Abbink P, Lemckert A, Ewald B, Lynch D, Denholtz M, et al. Comparative 
seroprevalence and immunogenicity of six rare serotype recombinant adenovirus 
vaccine vectors from subgroups B and D. J Virol. 2007;81(9):4654-63. 
[119] Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S HM, Truitt DM, Sumida 
SM, Kishko MG, Arthur JC, Korioth-Schmitz B, Newberg MH, Gorgone DA, Lifton MA, 
Panicali DL, Nabel GJ, Letvin NL, Goudsmit J. Immunogenicity of recombinant 
adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J 
Immunol. 2004;172(10):6290-7. 
[120] Paoletti E, Tartaglia J, Taylor J. Safe and effective poxvirus vectors--NYVAC and 
ALVAC. Dev Biol Stand. 1994;82:65-9. 
[121] Drexler I, Staib C, Sutter G. Modified vaccinia virus Ankara as antigen delivery 
system: how can we best use its potential? Curr Opin Biotechnol. 2004;15:506-12. 
[122] Greenough TC, Cunningham CK, Muresan P, McManus M, Persaud D, Fenton T, et al. 
Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on 
highly active antiretroviral therapy. Vaccine. 2008;26:6883-93. 
[123] Vasan S, Schlesinger SJ, Chen Z, Hurley A, Lombardo A, Than S, et al. Phase 1 safety 
and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-
HIV-1 B'/C candidate vaccine. PLoS One. 2010;5(1):e8816. 
[124] Quakkelaar ED, Redeker A, Haddad EK, Harari A, McCaughey SM, Duhen T, et al. 
Improved innate and adaptive immunostimulation by genetically modified HIV-1 
protein expressing NYVAC vectors. PLoS One. 2011;6(2):e16819. 
[125] McCormack S, Stohr W, Barber T, Bart P-A, Harari A, Moog C, et al. EV02: a Phase I 
trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost 
to NYVAC-C alone. Vaccine. 2008;26:3162-74. 
[126] Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. 
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N 
Engl J Med. 2009;361:2209-20. 
[127] Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, et al. Vaccine protection 
against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. 
Nature. 2012;Jan 4. 
[128] Esslinger C, Romero P, MacDonald HR. Efficient transduction of dendritic cells and 
induction of a T-cell response by third-generation lentivectors. Hum Gene Ther. 
2002;13:1091-100. 
 Immunodeficiency 64 
[129] Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, et al. In vivo gene 
delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 
1996;272:263-7. 
[130] He Y, Zhang J, Donahue C, Falo LD. Skin-derived dendritic cells induce potent CD8(+) 
T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity. 
2006;24:643-56. 
[131] Dai B, Yang L, Yang H, Hu B, Baltimore D, Wang P. HIV-1 Gag-specific immunity 
induced by a lentivector-based vaccine directed to dendritic cells. PNAS. 
2009;106:20382-7. 
[132] Lemiale F, Asefa B, Ye D, Chen C, Korokhov N, Humeau L. An HIV-based lentiviral 
vector as HIV vaccine candidate: Immunogenic characterization. Vaccine. 2010;28:1952-
61. 
[133] Iglesias MC, Mollier K, Beignon A-S, Souque P, Adotevi O, Lemonnier F, et al. 
Lentiviral vectors encoding HIV-1 polyepitopes induce broad CTL responses in vivo. 
Mol Ther. 2007;15:1203-10. 
[134] Levine BL, Humeau LM, Boyer J, MacGregor R-R, Rebello T, Lu X, et al. Gene transfer 
in humans using a conditionally replicating lentiviral vector. PNAS. 2006;103:17372-7. 
[135] Lemiale F, Korokhov N. Lentiviral vectors for HIV disease prevention and treatment. 
Vaccine. 2009;27:3443-9. 
[136] Walker BD, Ahmed R, Plotkin S. Moving ahead an HIV vaccine: use both arms to beat 
HIV. Nat Med. 2011;17(10):1194-5. 
[137] Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Sies sD, Drummond D, et al. 
Effector memory T cell responses are associated with protection of rhesus monkeys 
from mucosal simian immunodeficiency virus challenge. Nat Med. 2009;15(3):293-9. 
[138] Buonaguro L, Devito C, Tornesello M, Schröder U, Wahren B, Hinkula J, et al. DNA-
VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 
systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine. 
2007;25(32):5968-77. 
[139] Carcelain G, Debre P, Autran B. Reconstitution of CD4+ T lymphocytes in HIV-
infected individuals following antiretroviral therapy. Curr Opin Immunol. 2001;13:483-
8. 
[140] Plana M, Garcia F, Gallart T, Miro JM, Gatell JM. Lack of T-cell proliferative response 
to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 
disease. Immunology Study Group of Spanish EARTH-1 Study. Lancet. 1998;352:1194-5. 
[141] Garcia F, Niebla G, Romeu J, Vidal C, Plana M, Ortega M, et al. Cerebrospinal fluid 
HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: 
support for the hypothesis of local virus replication. AIDS. 1999 Aug 20;13(12):1491-6. 
[142] Smith KY. Selected metabolic and morphologic complications associated with highly 
active antiretroviral therapy. J Infect Dis. 2002;185 Suppl 2:123-7. 
[143] Rinaldo CR. Dendritic cell-based human immunodeficiency virus vaccine. J Intern 
Med. 2009 Jan;265(1):138-58. 
 
“Wrapped Up” Vaccines in the Context of HIV-1 Immunotherapy 65 
[144] Hel Z, Nacsa J, Tryniszewska E, Tsai W-P, Parks RW, Montefiori DC, et al. 
Containment of simian immunodeficiency virus infection in vaccinated macaques: 
correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ 
T cell responses. J Immunol. 2002;169:4778-87. 
[145] Day CL, Walker BD. Progress in defining CD4 helper cell responses in chronic viral 
infections. J Exp Med. 2003;198:1773-7. 
[146] Aiuti F, Mezzaroma I. Failure to reconstitute CD4+ T-cells despite suppression of HIV 
replication under HAART. AIDS Rev. 2006;8(2):88-97. 
[147] Yang OO, Sarkis PTN, Trocha A, Kalams SA, Johnson RP, Walker BD. Impacts of 
avidity and specificity on the antiviral efficiency of HIV-1-specific CTL. J Immunol. 
2003;171:3718-24. 
[148] Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat 
Rev Immunol. 2005;5:296-306. 
[149] Reis e Sousa C. Dendritic cells as sensors of infection. Immunity. 2001 May;14(5):495-8. 
[150] Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol. 2006;6:476-83. 
[151] Van Gulck E, Van Tendeloo VF, Berneman ZN, Vanham G. Role of dendritic cells in 
HIV-immunotherapy. Curr HIV Res. 2010 Jun;8(4):310-22. 
[152] Idoyaga J, Steinman RM. SnapShot: Dendritic Cells. Cell. 2011;146:660. 
[153] Zhang Z, Wang F. Plasmacytoid dendritic cells act as the most competent cell type in 
linking antiviral innate and adaptive immune responses. Cell Mol Immunol. 
2005;2(6):411-7. 
[154] Kadowaki N, Ho S, Antonenko S, Malefyt R, Kastelein R, Bazan F, et al. Subsets of 
human dendritic cell precursors express different toll-like receptors and respond to 
different microbial antigens. J Exp Med. 2001;194(6):863-9. 
[155] Donaghy H, Gazzard B, Gotch F, Patterson S. Dysfunction and infection of freshly 
isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-
1. Blood. 2003;101(11):4505-11. 
[156] Granelli-Piperno A, Golebiowska A, Trumpfheller C, Siegal FP, Steinman RM. HIV-1-
infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-
10 production and T cell regulation. Proc Natl Acad Sci U S A. 2004;101:7669-74. 
[157] Izquierdo-Useros N, Naranjo-Gomez M, Erkizia I, Puertas MC, Borràs FE, Blanco J, et 
al. HIV and mature dendritic cells: Trojan exosomes riding the Trojan horse? PLoS 
Pathog. 2010;6(3):e1000740. 
[158] Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, et al. 
Proliferating dendritic cell progenitors in human blood. J Exp Med. 1994 Jul 1;180(1):83-
93. 
[159] Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured 
human dendritic cells is maintained by granulocyte/macrophage colony-stimulating 
factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 
1994;179(4):1109-18. 
 Immunodeficiency 66 
[160] Lu W, Andrieu JM. In vitro human immunodeficiency virus eradication by autologous 
CD8(+) T cells expanded with inactivated-virus-pulsed dendritic cells. J Virol. 2001 
Oct;75(19):8949-56. 
[161] Aline F, Brand D, Bout D, Pierre J, Fouquenet D, Verrier B, et al. Generation of specific 
Th1 and CD8 T-cell responses by immunization with mouse CD8 dendritic cells loaded 
with HIV-1 viral lysate or envelope glycoproteins. Microbes Infect. 2007;9(4):536-43. 
[162] Huang X-L, Fan Z, Zheng L, Borowski L, Li H, Thomas EK, et al. Priming of human 
immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cell responses by dendritic cells 
loaded with HIV-1 proteins. J Infect Dis. 2003;187:315-9. 
[163] Fan Z, Huang X, Borowski L, Mellors J, Rinaldo CJ. Restoration of anti-human 
immunodeficiency virus type 1 (HIV-1) responses in CD8 T cells from late-stage 
patients on prolonged antiretroviral therapy by stimulation in vitro with HIV-1 protein-
loaded dendritic cells. J Virol. 2001;75(9):4413-9. 
[164] Huang X-L, Fan Z, Colleton B, Buchli R, Li H, Hildebrand W, et al. Processing and 
presentation of exogenous HLA class I peptides by dendritic cells from human 
immunodeficiency virus type 1-infected persons. J Virol. 2005;79(5):3052-62. 
[165] Engelmayer J, Larsson M, Lee A, Lee M, Cox W, Steinman R, et al. Mature dendritic 
cells infected with canarypox virus elicit strong anti-human immunodeficiency virus 
CD8 and CD4 T-cell responses from chronically infected individuals. J Virol. 
2001;75(5):2142-53. 
[166] Guerra S, Nájera J, González J, López-Fernández L, Climent N, Gatell J, et al. Distinct 
gene expression profiling after infection of immature human monocyte-derived 
dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol. 
2007;81(16):8707-21. 
[167] Gudmundsdotter L, Wahren B, Haller B, Boberg A, Edbäck U, Bernasconi D, et al. 
Amplified antigen-specific immune responses in HIV-1 infected individuals in a double 
blind DNA immunization and therapy interruption trial. Vaccine. 2011;29(33):5558-66. 
[168] Chassin D, Andrieu M, Cohen W, Culmann-Penciolelli B, Ostankovitch M, Hanau D, 
et al. Dendritic cells transfected with the nef genes of HIV-1 primary isolates specifically 
activate cytotoxic T lymphocytes from seropositive subjects. Eur J Immunol. 1999 
Jan;29(1):196-202. 
[169] Kavanagh DG, Kaufmann DE, Sunderji S, Frahm N, Le Gall S, Boczkowski D, et al. 
Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with 
mRNA encoding cytoplasm- or lysosome-targeted Nef. Blood. 2006 Mar 1;107(5):1963-9. 
[170] Van Gulck ER, Ponsaerts P, Heyndrickx L, Vereecken K, Moerman F, De Roo A, et al. 
Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with 
mRNA encoding autologous HIV-1 Gag and Env proteins. Blood. 2006 Mar 
1;107(5):1818-27. 
[171] Van Gulck ER, Vanham G, Heyndrickx L, Coppens S, Vereecken K, Atkinson D, et al. 
Efficient in vitro expansion of human immunodeficiency virus (HIV)-specific T-cell 
 
“Wrapped Up” Vaccines in the Context of HIV-1 Immunotherapy 67 
responses by gag mRNA-electroporated dendritic cells from treated and untreated HIV 
type 1-infected individuals. J Virol. 2008 Apr;82(7):3561-73. 
[172] Weissman D, Ni H, Scales D, Dude A, Capodici J, McGibney K, et al. HIV gag mRNA 
transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II 
molecules, causes DC maturation, and induces a potent human in vitro primary 
immune response. J Immunol. 2000;165(8):4710-7. 
[173] Garcia F, Routy J-P. Challenges in dendritic cells-based therapeutic vaccination in 
HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1. 
Vaccine. 2011;29:6454-63. 
[174] Lisziewicz J, Trocio J, Whitman L, Varga G, Xu J, Bakare N, et al. DermaVir: a novel 
topical vaccine for HIV/AIDS. J Invest Dermatol. 2005 Jan;124(1):160-9. 
[175] Allard SD, De Keersmaecker B, de Goede AL, Verschuren EJ, Koetsveld J, Reedijk ML, 
et al. A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and 
Nef expressing dendritic cells followed by treatment interruption. Clin Immunol. 
2012;142(3):252-6. 
[176] Van Gulck E, Vlieghe E, Vekemans M, Van Tendeloo VFI, Van De Velde A, Smits E, et 
al. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in 
HIV-1-infected patients. AIDS. 2011;26(4):F1-F12. 
[177] Angel JB, Routy J-P, Tremblay C, Ayers D, Woods R, Singer J, et al. A randomized 
controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune. 
AIDS. 2011;25(6):731-9. 
[178] Elsabahy M, Nazarali A, Foldvari M. Non-viral nucleic acid delivery: key challenges 
and future directions. Curr Drug Deliv. 2011;8(3):235-44. 
[179] De Temmerman M-L, Rejman J, Demeester J, Irvine D, Gander B, De Smedt S. 
Particulate vaccines: on the quest for optimal delivery and immune response. Drug 
Discov Today. 2011;16(13-14):569-82. 
[180] Bachmann MF, Jennings G. Vaccine delivery: a matter of size, geometry, kinetics and 
molecular patterns. Nat Rev Immunol. 2010;10(11):787-96. 
[181] Demento SL, Siefert A, Bandyopadhyay A, Sharp F, Fahmy T. Pathogen-associated 
molecular patterns on biomaterials: a paradigm for engineering new vaccines. Trends 
Biotechnol. 2011;29(6):294-306. 
[182] Heit A, Schmitz F, Haas T, Busch DH, Wagner H. Antigen co-encapsulated with 
adjuvants efficiently drive protective T cell immunity. Eur J Immunol. 2007 
Aug;37(8):2063-74. 
[183] Schlosser E, Mueller M, Fischer S, Basta S, Busch D, Gander B, et al. TLR ligands and 
antigen need to be coencapsulated into the same biodegradable microsphere for the 
generation of potent cytotoxic T lymphocyte responses. Vaccine. 2008;26(13):1626-37. 
[184] De Haes W, De Koker S, Pollard C, Atkinson D, Vlieghe E, Hoste J, et al. 
Polyelectrolyte capsules-containing HIV-1 p24 and poly I:C modulate dendritic cells to 
stimulate HIV-1-specific immune responses. Mol Ther. 2010 Jul;18(7):1408-16. 
 Immunodeficiency 68 
[185] Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. 
Curr Top Microbiol Immunol. 2006;311:17-58. 
[186] De Koker S, De Geest BG, SK. S, R. DR, T. N, Y. VK, et al. Polyelectrolyte 
microcapsules as antigen delivery vehicles to dendritic cells: uptake, processing, and 
cross-presentation of encapsulated antigens. Angew Chem Int Ed Engl. 
2009;48(45):8485-9. 
[187] De Koker S, Lambrecht BN, Willart MA, van Kooyk Y, Grooten J, Vervaet C, et al. 
Designing polymeric particles for antigen delivery. Chem Soc Rev. 2011;40:320-39. 
[188] Trono D, Van Lint C, Rouzioux C, Verdin E, Barre-Sinoussi F, Chun TW, et al. HIV 
persistence and the prospect of long-term drug-free remissions for HIV-infected 
individuals. Science. 2010 Jul 9;329(5988):174-80. 
[189] Tavernier G, Andries O, Demeester J, Sanders NN, De Smedt SC, Rejman J. mRNA as 
gene therapeutic: How to control protein expression. J Control Release. 2010 Oct 
21;150(3):238-91. 
[190] Lori F, Calarota SA, Lisziewicz J. Nanochemistry-based immunotherapy for HIV-1. 
Curr Med Chem. 2007;14:1911-9. 
[191] Rejman J, Tavernier G, Bavarsad N, Demeester J, De Smedt SC. mRNA transfection of 
cervical carcinoma and mesenchymal stem cells mediated by cationic carriers. J Control 
Release. 2010 Nov 1;147(3):385-91. 
[192] Bettinger T, Carlisle RC, Read ML, Ogris M, Seymour LW. Peptide-mediated RNA 
delivery: a novel approach for enhanced transfection of primary and post-mitotic cells. 
Nucleic Acids Res. 2001;29(18):3882-91. 
[193] Pascolo S. Vaccination with messenger RNA (mRNA). Handb Exp Pharmacol. 
2008(183):221-35. 
[194] Roesler E, Weiss R, Weinberger EE, Fruehwirth A, Stoecklinger A, Mostbock S, et al. 
Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 
allergens. J Allergy Clin Immunol. 2009 Nov;124(5):1070-7. 
[195] Weiss R, Scheiblhofer S, Roesler E, Ferreira F, Thalhamer J. Prophylactic mRNA 
vaccination against allergy. Curr Opin Allergy Clin Immunol. 2010;10:567-74. 
[196] Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, et 
al. Induction of complete and molecular remissions in acute myeloid leukemia by 
Wilms' tumor 1 antigen-targeted dendritic cell vaccination. PNAS. 2010 Aug 
3;107(31):13824-9. 
[197] Weide B, Carralot JP, Reese A, Scheel B, Eigentler TK, Hoerr I, et al. Results of the first 
phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother. 2008 
Feb-Mar;31(2):180-8. 
[198] Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. 
Immunol Rev. 2004;199:251-63. 
[199] Newman KD, Elamanchili P, Kwon GS, Samuel J. Uptake of poly(D,L-lactic-co-glycolic 
acid) microspheres by antigen-presenting cells in vivo. J Biomed Mater Res. 2002;60:480-
6. 
 
“Wrapped Up” Vaccines in the Context of HIV-1 Immunotherapy 69 
[200] Waeckerle-Men Y, Allmen EU, Gander B, Scandella E, Schlosser E, Schmidtke G, et al. 
Encapsulation of proteins and peptides into biodegradable poly(D,L-lactide-co-
glycolide) microspheres prolongs and enhances antigen presentation by human 
dendritic cells. Vaccine. 2006 Mar 10;24(11):1847-57. 
[201] Fischer S, Uetz-von Allmen E, Waeckerle-Men Y, Groettrup M, Merkle HP, Gander B. 
The preservation of phenotype and functionality of dendritic cells upon phagocytosis of 
polyelectrolyte-coated PLGA microparticles. Biomaterials. 2007 Feb;28(6):994-1004. 
[202] Waeckerle-Men Y, Scandella E, Uetz-Von Allmen E, Ludewig B, Gillessen S, Merkle 
HP, et al. Phenotype and functional analysis of human monocyte-derived dendritic cells 
loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy. 
J Immunol Methods. 2004 Apr;287(1-2):109-24. 
[203] Kempf M, Mandal B, Jilek S, Thiele L, Voros J, Textor M, et al. Improved stimulation of 
human dendritic cells by receptor engagement with surface-modified microparticles. J 
Drug Target. 2003;11:11-8. 
[204] Wischke C, Zimmermann J, Wessinger B, Schendler A, Borchert HH, Peters JH, et al. 
Poly(I:C) coated PLGA microparticles induce dendritic cell maturation. Int J Pharm. 
2009 Jan 5;365(1-2):61-8. 
[205] Elamanchili P, Diwan M, Cao M, Samuel J. Characterization of poly(D,L-lactic-co-
glycolic acid) based nanoparticulate system for enhanced delivery of antigens to 
dendritic cells. Vaccine. 2004 Jun 23;22(19):2406-12. 
[206] Aline F, Brand D, Pierre J, Roingeard P, Severine M, Verrier B, et al. Dendritic cells 
loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles 
induce enhanced cellular immune responses against HIV-1 after vaccination. Vaccine. 
2009 May 27;9(4):536-43. 
[207] Ataman-Onal Y, Munier S, Ganee A, Terrat C, Durand PY, Battail N, et al. Surfactant-
free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced 
cellular and humoral immune responses in various animal models. J Control Release. 
2006 May 15;112(2):175-85. 
[208] Tamber H, Johansen P, Merkle HP, Gander B. Formulation aspects of biodegradable 
polymeric microspheres for antigen delivery. Adv Drug Deliv Rev. 2005;57:357-76. 
[209] Kazzaz J, Neidleman J, Singh M, Ott G, O'Hagan DT. Novel anionic microparticles are 
a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 
gag from HIV-1. J Control Release. 2000;67:347-56. 
[210] Lamalle-Bernard D, Munier S, Compagnon C, Charles M-H, Kalyanaraman VS, Delair 
T, et al. Coadsorption of HIV-1 p24 and gp120 proteins to surfactant-free anionic PLA 
nanoparticles preserves antigenicity and immunogenicity. J Control Release. 
2006;115:57-67. 
[211] Johansen P, Martinez Gomez JM, Gander B. Development of synthetic biodegradable 
microparticulate vaccines: a roller coaster story. Expert Rev Vaccines. 2007;6:471-4. 
 Immunodeficiency 70 
[212] Walter E, Moelling K, Pavlovic J, Merkle HP. Microencapsulation of DNA using 
poly(DL-lactide-co-glycolide): stability issues and release characteristics. J Control 
Release. 1999;61:361-74. 
[213] Remaut K, Sanders NN, De Geest BG, Braeckmans K, Demeester J, De Smedt SC. 
Nucleic acid delivery: Where material sciences and bio-sciences meet. Materials Science 
and Engineering R. 2007;58:117-61. 
[214] Basarkar A, Devineni D, Palaniappan R, Singh J. Preparation, characterization, 
cytotoxicity and transfection efficiency of poly(DL-lactide-co-glycolide) and poly(DL-
lactic acid) cationic nanoparticles for controlled delivery of plasmid DNA. Int J Pharm. 
2007;343:247-2 
[215]  
[216] Donath E, Sukhorukov GB, Caruso F, Davis DA, Mohwald H. Novel hollow polymer 
shells by colloid-templated assembly of polyelectrolytes. Angewandte Chemie-
International Edition. 1998;37:2202-5. 
[217] De Koker S, De Geest BG, Cubelier C, Ferdinande L, Deckers W, Hennick WE, et al. In 
vivo cellular uptake, degradation and biocompatibility of polyelectrolyte 
microcapsules. Advanced Functional Materials. 2007;17: 3754-63. 
[218] De Rose R, Zelikin AN, Johnston APR, Sexton A, Chong SF, Cortez C, et al. Binding, 
Internalization, and Antigen Presentation of Vaccine-Loaded Nanoengineered Capsules 
in Blood. Advanced Materials. 2008;20:1-6. 
[219] Chong S-F, Sexton A, De Rose R, Kent SJ, Zelikin AN, Caruso F. A paradigm for 
peptide vaccine delivery using viral epitopes encapsulated in degradable polymer 
hydrogel capsules. Biomaterials. 2009;30:5178-86. 
[220] Zelikin AN, Li Q, Caruso F. Degradable polyelectrolyte capsules filled with 
oligonucleotide sequences. Angew Chem Int Ed Engl. 2006;45:7743-45. 
[221] Selina OE, Belov SI, Vlasova NN, Balysheva VI, Churin AI, Bartkoviak A, et al. 
Biodegradable microcapsules containing DNA for the new DNA vaccine design. Bioorg 
Khim. 2009;35:113-21. 
[222] Tiera MJ, Qiu X-P, Bechaouch S, Shi Q, Fernandes JC, Winnik FM. Synthesis and 
characterization of phosphorylcholine-substituted chitosans soluble in physiological pH 
conditions. Biomacromolecules. 2006;7:3151-6. 
[223] Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, et al. A 
versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: 
polyethylenimine. PNAS. 1995;92:7297-301. 
[224] Godbey WT, Wu KK, Mikos AG. Poly(ethylenimine) and its role in gene delivery. J 
Control Release. 1999;60:149-60. 
[225] Itaka K, Harada A, Yamasaki Y, Nakamura K, Kawaguchi H, Kataoka K. In situ single 
cell observation by fluorescence resonance energy transfer reveals fast intra-cytoplasmic 
delivery and easy release of plasmid DNA complexed with linear polyethylenimine. J 
Gene Med. 2004;6:76-84. 
 
“Wrapped Up” Vaccines in the Context of HIV-1 Immunotherapy 71 
[226] Sonawane ND, Szoka FC, Verkman AS. Chloride accumulation and swelling in 
endosomes enhances DNA transfer by polyamine-DNA polyplexes. J Biol Chem. 
2003;278:44826-31. 
[227] Behr JP. The proton sponge: A trick to enter cells the viruses did not exploit. Chimia. 
1997;51:34-6. 
[228] Lori F, Trocio J, Bakare N, Kelly LM, Lisziewicz J. DermaVir, a novel HIV 
immunisation technology. Vaccine. 2005 Mar 18;23(17-18):2030-4. 
[229] Lisziewicz J, Trocio J, Xu J, Whitman L, Ryder A, Bakare N, et al. Control of viral 
rebound through therapeutic immunization with DermaVir. Aids. 2005 Jan 3;19(1):35-
43. 
[230] Lisziewicz J. Conference scene--active immunotherapeutics forum: meeting highlights. 
Immunotherapy. 2009;1:743-8. 
[231] Wahren B, Biswas P, Borggren M, Coleman A, Da Costa K, De Haes W, et al. Rational 
design of HIV vaccine and microbicides: report of the EUROPRISE annual conference. J 
Transl Med. 2010;8:72. 
[232] Felnerova D, Viret J-F, Gluck R, Moser C. Liposomes and virosomes as delivery 
systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol. 2004;15:518-29. 
[233] Alving CR. Liposomes as carriers of antigens and adjuvants. J Immunol Methods. 
1991;140:1-13. 
[234] Nakanishi T, Kunisawa J, Hayashi A, Tsutsumi Y, Kubo K, Nakagawa S, et al. 
Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-
mediated immune response to soluble proteins. J Control Release. 1999;61:233-40. 
[235] Moser C, Metcalfe IC, Viret J-F. Virosomal adjuvanted antigen delivery systems. 
Expert Rev Vaccines. 2003;2:189-96. 
[236] Zheng L, Huang XL, Fan Z, Borowski L, Wilson CC, Rinaldo CR. Delivery of 
liposome-encapsulated HIV type 1 proteins to human dendritic cells for stimulation of 
HIV type 1-specific memory cytotoxic T lymphocyte responses. AIDS Res Hum 
Retroviruses. 1999;15:1011-20. 
[237] Steers NJ, Peachman KK, McClain S, Alving CR, Rao M. Liposome-encapsulated HIV-
1 Gag p24 containing lipid A induces effector CD4+ T-cells, memory CD8+ T-cells, and 
pro-inflammatory cytokines. Vaccine. 2009 Nov 16;27(49):6939-49. 
[238] Andrieu M, Desoutter J-F, Loing E, Gaston J, Hanau D, Guillet J-G, et al. Two human 
immunodeficiency virus vaccinal lipopeptides follow different cross-presentation 
pathways in human dendritic cells. J Virol. 2003;77:1564-70. 
[239] Gahery H, Daniel N, Charmeteau B, Ourth L, Jackson A, Andrieu M, et al. New CD4+ 
and CD8+ T cell responses induced in chronically HIV type-1-infected patients after 
immunizations with an HIV type 1 lipopeptide vaccine. AIDS Res Hum Retroviruses. 
2006;22:684-94. 
[240] Pialoux G, Quercia RP, Gahery H, Daniel N, Slama L, Girard P-M, et al. 
Immunological responses and long-term treatment interruption after human 
 Immunodeficiency 72 
immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected 
patients: the LIPTHERA study. Clin Vaccine Immunol. 2008;15:562-8. 
[241] Cobb A, Roberts LK, Palucka AK, Mead H, Montes M, Ranganathan R, et al. 
Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine. J 
Immunol Methods. 2011;365:27-37. 
[242] Simberg D, Weisman S, Talmon Y, Barenholz Y. DOTAP (and other cationic lipids): 
chemistry, biophysics, and transfection. Crit Rev Ther Drug Carrier Syst. 2004;21:257-
317. 
[243] Tresset G. The multiple faces of self-assembled lipidic systems. PMC Biophys. 
2009;2(1):3-28. 
[244] Rejman J, Bragonzi A, Conese M. Role of clathrin- and caveolae-mediated endocytosis 
in gene transfer mediated by lipo- and polyplexes. Mol Ther. 2005;12:468-74. 
[245] Rejman J, Conese M, Hoekstra D. Gene transfer by means of lipo- and polyplexes: role 
of clathrin and caveolae-mediated endocytosis. J Liposome Res. 2006;16:237-47. 
[246] Zuhorn IS, Kalicharan R, Hoekstra D. Lipoplex-mediated transfection of mammalian 
cells occurs through the cholesterol-dependent clathrin-mediated pathway of 
endocytosis. J Biol Chem. 2002;277:18021-8. 
[247] Xu Y, Szoka FC. Mechanism of DNA release from cationic liposome/DNA complexes 
used in cell transfection. Biochemistry. 1996;35:5616-23. 
[248] Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD, Potter TA. Lipid-DNA 
complexes induce potent activation of innate immune responses and antitumor activity 
when administered intravenously. J Immunol. 1999;163:1552-61. 
[249] Jiao X, Wang RYH, Feng Z, Alter HJ, Shih JW-K. Modulation of cellular immune 
response against hepatitis C virus nonstructural protein 3 by cationic liposome 
encapsulated DNA immunization. Hepatology. 2003;37:452-60. 
[250] Perrie Y, Obrenovic M, McCarthy D, Gregoriadis G. Liposome (Lipodine)-mediated 
DNA vaccination by the oral route. J Liposome Res. 2002;12:185-97. 
[251] Malone RW, Felgner PL, Verma IM. Cationic liposome-mediated RNA transfection. 
Proc Natl Acad Sci U S A. 1989 Aug;86(16):6077-81. 
[252] Zohra FT, Chowdhury EH, Nagaoka M, Akaike T. Drastic effect of nanoapatite 
particles on liposome-mediated mRNA delivery to mammalian cells. Anal Biochem. 
2005;345:164-6. 
[253] Zou S, Scarfo K, Nantz MH, Hecker JG. Lipid-mediated delivery of RNA is more 
efficient than delivery of DNA in non-dividing cells. Int J Pharm. 2010;389:232-43. 
[254] Canelle L, Bousquet J, Pionneau C, Hardouin J, Choquet-Kastylevsky G, Joubert-Caron 
R, et al. A proteomic approach to investigate potential biomarkers directed against 
membrane-associated breast cancer proteins. Electrophoresis. 2006 Apr;27(8):1609-16. 
[255] Martinon F, Krishnan S, Lenzen G, Magne R, Gomard E, Guillet JG, et al. Induction of 
virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J 
Immunol. 1993 Jul;23(7):1719-22. 
 
“Wrapped Up” Vaccines in the Context of HIV-1 Immunotherapy 73 
[256] Dell K, Klein C, Gissmann L. Comparison of DNA- and mRNA-transfected mouse 
dendritic cells as potential vaccines against the human papillomavirus type 16 
associated oncoprotein E7. Antivir Ther. 2008;13:495-509. 
[257] Yu H, Babiuk LA, van Drunen Littel-van den Hurk S. Immunity and protection by 
adoptive transfer of dendritic cells transfected with hepatitis C NS3/4A mRNA. 
Vaccine. 2007;25:1701-11. 
[258] Senior JH, Trimble KR, Maskiewicz R. Interaction of positively-charged liposomes 
with blood: implications for their application in vivo. Biochim Biophys Acta. 
1991;1070:173-9. 
[259] Simberg D, Weisman S, Talmon Y, Faerman A, Shoshani T, Barenholz Y. The role of 
organ vascularization and lipoplex-serum initial contact in intravenous murine 
lipofection. J Biol Chem. 2003;278:39858-65. 
[260] Zuhorn IS, Visser WH, Bakowsky U, Engberts JBFN, Hoekstra D. Interference of 
serum with lipoplex-cell interaction: modulation of intracellular processing. Biochim 
Biophys Acta. 2002;1560:25-36. 
[261] Bhadra D, Bhadra S, Jain P, Jain NK. Pegnology: a review of PEG-ylated systems. 
Pharmazie. 2002;57:5-29. 
[262] Singh SK, Bisen PS. Adjuvanticity of stealth liposomes on the immunogenicity of 
synthetic gp41 epitope of HIV-1. Vaccine. 2006;24(19):4161-6. 
[263] Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles 
via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J. 
2004;377:159-69. 
[264] Burgdorf S, Kurts C. Endocytosis mechanisms and the cell biology of antigen 
presentation. Curr Opin Immunol. 2008;20:89-95. 
[265] Brewer JM, Pollock KGJ, Tetley L, Russell DG. Vesicle size influences the trafficking, 
processing, and presentation of antigens in lipid vesicles. J Immunol. 2004;173:6143-50. 
[266] Ackerman AL, Kyritsis C, Tampe R, Cresswell P. Early phagosomes in dendritic cells 
form a cellular compartment sufficient for cross presentation of exogenous antigens. 
Proc Natl Acad Sci U S A. 2003;100(22):12889-94. 
[267] Burgdorf S, Kautz A, Bohnert V, Knolle PA, Kurts C. Distinct pathways of antigen 
uptake and intracellular routing in CD4 and CD8 T cell activation. Science. 
2007;316:612-6. 
[268] Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic 
applications. Nat Rev Drug Discov. 2010;9:615-27. 
[269] Engering A, Geijtenbeek TBH, van Vliet SJ, Wijers M, van Liempt E, Demaurex N, et 
al. The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for 
presentation to T cells. J Immunol. 2002;168:2118-26. 
[270] Hattori Y, Kawakami S, Nakamura K, Yamashita F, Hashida M. Efficient gene transfer 
into macrophages and dendritic cells by in vivo gene delivery with mannosylated 
lipoplex via the intraperitoneal route. J Pharmacol Exp Ther. 2006;318:828-34. 
 Immunodeficiency 74 
[271] Lu Y, Kawakami S, Yamashita F, Hashida M. Development of an antigen-presenting 
cell-targeted DNA vaccine against melanoma by mannosylated liposomes. Biomaterials. 
2007;28:3255-62. 
[272] Sheng K-C, Kalkanidis M, Pouniotis DS, Esparon S, Tang CK, Apostolopoulos V, et al. 
Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity 
in vitro and in vivo. Eur J Immunol. 2008;38:424-36. 
[273] Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S-I, Soares H, et al. In 
vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor 
improves T cell vaccination. J Exp Med. 2004;199:815-24. 
[274] Connolly NC, Colleton BA, Rinaldo CR. Treating HIV-1 infection with dendritic cells. 
Curr Opin Mol Ther. 2007;9:353-63. 
[275] Gieseler RK, Marquitan G, Hahn MJ, Perdon LA, Driessen WHP, Sullivan SM, et al. 
DC-SIGN-specific liposomal targeting and selective intracellular compound delivery to 
human myeloid dendritic cells: implications for HIV disease. Scand J Immunol. 
2004;59:415-24. 
[276] Tacken PJ, de Vries IJM, Gijzen K, Joosten B, Wu D, Rother RP, et al. Effective 
induction of naive and recall T-cell responses by targeting antigen to human dendritic 
cells via a humanized anti-DC-SIGN antibody. Blood. 2005;106:1278-85. 
[277] Altin JG, Parish CR. Liposomal vaccines--targeting the delivery of antigen. Methods. 
2006;40:39-52. 
[278] Altin JG, White FA, Easton CJ. Synthesis of the chelator lipid nitrilotriacetic acid 
ditetradecylamine (NTA-DTDA) and its use with the IAsys biosensor to study receptor-
ligand interactions on model membranes. Biochim Biophys Acta. 2001;1513:131-48. 
[279] Faham A, Altin JG. Antigen-containing liposomes engrafted with flagellin-related 
peptides are effective vaccines that can induce potent antitumor immunity and 
immunotherapeutic effect. J Immunol. 2010;185:1744-54. 
[280] Resh MD. Palmitoylation of ligands, receptors, and intracellular signaling molecules. 
Sci STKE. 2006;2006(359):re14. 
[281] Blander JM, Medzhitov R. Regulation of phagosome maturation by signals from toll-
like receptors. Science. 2004;304:1014-18. 
[282] Nicholls EF, Madera L, Hancock REW. Immunomodulators as adjuvants for vaccines 
and antimicrobial therapy. Ann N Y Acad Sci. 2010;1213:46-61. 
[283] Baylor NW, Egan W, Richman P. Aluminum salts in vaccines--US perspective. 
Vaccine. 2002;20 (Suppl 3):18-23. 
[284] Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for 
presentation by dendritic cells. Nature. 2006 Apr 6;440(7085):808-12. 
[285] Ennis FA, Cruz J, Jameson J, Klein M, Burt D, Thipphawong J. Augmentation of 
human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine 
and adjuvanted carriers (ISCOMS). Virology. 1999;259:256-61. 
[286] Rimmelzwaan GF, Nieuwkoop N, Brandenburg A, Sutter G, Beyer WE, Maher D, et al. 
A randomized, double blind study in young healthy adults comparing cell mediated 
 
“Wrapped Up” Vaccines in the Context of HIV-1 Immunotherapy 75 
and humoral immune responses induced by influenza ISCOM vaccines and 
conventional vaccines. Vaccine. 2000;19:1180-7. 
[287] Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, et al. 
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated 
antibody and CD4(+) and CD8(+) T cell responses in humans. PNAS. 2004;101:10697-
702. 
[288] Akerblom L, Nara P, Dunlop N, Putney S, Morein B. HIV experimental vaccines based 
on the iscom technology using envelope and GAG gene products. Biotechnol Ther. 
1993;4(3-4):145-61. 
[289] Putkonen P, Bjorling E, Akerblom L, Thorstensson R, Lovgren K, Benthin L, et al. 
Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom 
vaccine. J Acquir Immune Defic Syndr. 1994;7:551-9. 
[290] Agrawal L, Haq W, Hanson CV, Rao DN. Generating neutralizing antibodies, Th1 
response and MHC non restricted immunogenicity of HIV-I env and gag peptides in 
liposomes and ISCOMs with in-built adjuvanticity. J Immune Based Ther Vaccines. 
2003;1(1):5. 
[291] Cox JC, Sjolander A, Barr IG. ISCOMs and other saponin based adjuvants. Adv Drug 
Deliv Rev. 1998;32:247-71. 
[292] Frazer IH, Quinn M, Nicklin JL, Tan J, Perrin LC, Ng P, et al. Phase 1 study of HPV16-
specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in 
women with cervical intraepithelial neoplasia. Vaccine. 2004;23:172-81. 
[293] Osterhaus A, de Vries P, Morein B, Akerblom L, Heeney J. Comparison of protection 
afforded by whole virus ISCOM versus MDP adjuvanted formalin-inactivated SIV 
vaccines from IV cell-free or cell-associated homologous challenge. AIDS Res Hum 
Retroviruses. 1992;8(8):1507-10. 
[294] Verschoor EJ, Mooij P, Oostermeijer H, van der Kolk M, ten Haaft P, Verstrepen B, et 
al. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated 
human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral 
clearance. J Virol. 1999;73(4):3292-300. 
[295] Koopman G, Bogers WMJM, van Gils M, Koornstra W, Barnett S, Morein B, et al. 
Comparison of intranasal with targeted lymph node immunization using PR8-Flu 
ISCOM adjuvanted HIV antigens in macaques. J Med Virol. 2007;79(5):474-82. 
[296] Morein B, Hu K-F, Abusugra I. Current status and potential application of ISCOMs in 
veterinary medicine. Adv Drug Deliv Rev. 2004;56:1367-82. 
[297] Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like 
receptors. Immunol Rev. 2004;199:227-50. 
[298] Schreibelt G, Tel J, Sliepen KHEWJ, Benitez-Ribas D, Figdor CG, Adema GJ, et al. Toll-
like receptor expression and function in human dendritic cell subsets: implications for 
dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother. 
2010;59(10):1573-82. 
 Immunodeficiency 76 
[299] Espuelas S, Roth A, Thumann C, Frisch B, Schuber F. Effect of synthetic lipopeptides 
formulated in liposomes on the maturation of human dendritic cells. Mol Immunol. 
2005;42:721-9. 
[300] Kazzaz J, Singh M, Ugozzoli M, Chesko J, Soenawan E, O'Hagan DT. Encapsulation of 
the immune potentiators MPL and RC529 in PLG microparticles enhances their 
potency. J Control Release. 2006 Feb 21;110(3):566-73. 
[301] Vandepapeliere P, Horsmans Y, Moris P, Van Mechelen M, Janssens M, Koutsoukos 
M, et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 
induce strong and persistent humoral and T cell responses against hepatitis B surface 
antigen in healthy adult volunteers. Vaccine. 2008;26:1375-86. 
[302] Fischer S, Schlosser E, Mueller M, Csaba N, Merkle HP, Groettrup M, et al. 
Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA 
microparticles induces cellular immune response. J Drug Target. 2009 Sep;17(8):652-61. 
[303] Demento SL, Bonafe N, Cui W, Kaech SM, Caplan MJ, Fikrig E, et al. TLR9-targeted 
biodegradable nanoparticles as immunization vectors protect against West Nile 
encephalitis. J Immunol. 2010;185:2989-97. 
[304] Li WM, Bally MB, Schutze-Redelmeier MP. Enhanced immune response to T-
independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes. 
Vaccine. 2001;20:148-57. 
[305] Singh M, Ott G, Kazzaz J, Ugozzoli M, Briones M, Donnelly J, et al. Cationic 
microparticles are an effective delivery system for immune stimulatory cpG DNA. 
Pharm Res. 2001;18:1476-9. 
[306] Johnston D, Zaidi B, Bystryn J-C. TLR7 imidazoquinoline ligand 3M-019 is a potent 
adjuvant for pure protein prototype vaccines. Cancer Immunol Immunother. 
2007;56:1133-41. 
[307] Westwood A, Elvin SJ, Healey GD, Williamson ED, Eyles JE. Immunological responses 
after immunisation of mice with microparticles containing antigen and single stranded 
RNA (polyuridylic acid). Vaccine. 2006;24:1736-43. 
[308] Trumpfheller C, Caskey M, Nchinda G, Longhi MP, Mizenina O, Huang Y, et al. The 
microbial mimic poly IC induces durable and protective CD4+ T cell immunity together 
with a dendritic cell targeted vaccine. PNAS. 2008 Feb 19;105(7):2574-9. 
[309] Zaks K, Jordan M, Guth A, Sellins K, Kedl R, Izzo A, et al. Efficient immunization and 
cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to 
cationic liposomes. J Immunol. 2006;176:7335-45. 
[310] Bonjardim CA, Ferreira PCP, Kroon EG. Interferons: signaling, antiviral and viral 
evasion. Immunol Lett. 2009;122:1-11. 
[311] Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev. 2009;227:75-86. 
[312] De Keersmaecker B, Heirman C, Corthals J, Empsen C, van Grunsven LA, Allard 
SD, et al. The combination of 4-1BBL and CD40L strongly enhances the capacity of 
dendritic cells to stimulate HIV-specific T cell responses. J Leukoc Biol. 2011 
Jun;89(6):989-99. 
